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Abstract 
Obesity is a growing epidemic often leading to metabolic disease, and immune 
dysregulation is an associated pathology. This dysregulation could be targeted 
therapeutically to minimise some of the negative effects of obesity, and mitigate pre-
diabetes pathogenesis. In this context, innate-like T cells appear to be a particularly 
suitable target as these T lymphocytes are responsive to their metabolic environment, 
and are highly enriched in adipose tissue, and are therefore in an ideal position to exert 
immunometabolic effects on the adipose tissue micro-environment. This project aimed 
to establish a novel methodology utilising spectral flow cytometry to study the 
immunometabolic regulation and function of innate-like T cells. Metabolic spectral flow 
cytometry enables single-cell quantification of functional and metabolic parameters, 
which is necessary to establish innate-like T cells as viable therapeutic targets, as well 
as increasing understanding of these cells in general. 
As access to adipose tissue was limited as a result of the COVID-19 pandemic, this 
thesis focusses on peripheral blood mononuclear cell (PBMC)-derived cells, and 
presents the necessary steps to develop a working flow cytometry panel, with the goal 
of using it to explore innate-like T cell metabolism in both PBMC and adipose tissue-
derived cells, from humans with and without metabolic disease. Validation has been 
conducted on PBMC from 10 healthy participants, with HbA1c measured as an 
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Obesity is a growing global epidemic which increases the risk for a number of 
metabolic diseases, particularly Type 2 diabetes mellitus (T2DM), but also 
cardiovascular disease, and some cancers.1-4 The rise in prevalence strongly indicates 
that current therapeutics and interventions are not working effectively and alternative 
treatment options are needed. As metabolic disease can be characterised by chronic 
inflammation caused by immune cell dysregulation,5 immunometabolism represents a 
promising novel option to better understand and treat metabolic disorders. Defined 
briefly, immunometabolism is a research concept involving the idea that immune cell 
function is driven and can be characterised by its metabolic state.6 Immune cells play an 
integral role in the exacerbation of metabolic disease, due to the two systems’ co-
evolution.7 Innate-like T (ILT) cells are an established subset of T lymphocytes that 
bridge the innate and adaptive arms of immunity.8 An association has been found 
between them and a plethora of diseases including obesity, diabetes, allergic asthma, 
autoimmune disease, cancer, and infectious disease, however they have predominantly 
been studied in isolation.2, 9-12 Due to their relative abundance in adipose tissue (AT),13 
ILT cells represent a promising avenue for development of novel therapeutics against 
obesity and its associated pathologies. This thesis draws from a review article published 
by me earlier this year.14 
1.1 Epidemiology of Obesity and Diabetes 
National and global estimates indicate that the prevalence of diabetes is trending 
upwards, and is predicted to increase at a steady rate.15-18 The most recent data estimates 
over 253,000 New Zealanders suffer from a form of diabetes.19 Risk factors for T2DM 
development, such as impaired insulin production and high blood glucose have been 
associated with abdominal and visceral obesity.20, 21 As such, obesity, characterised as 
2 
an excess of fatty acids stored in AT, is a major contributing factor for insulin resistance 
and T2DM.22 It is therefore unsurprising that, similar to diabetes, the global incidence 
of obesity has increased in recent decades.23, 24 In New Zealand, 30.9% of people aged 
15 and over are obese. This reflects an increase of 4.4% in just over 10 years. By 
ethnicity, 66.5% of Pasifika, 48.2% of Māori, 29.1% of European/Other, and 13.8% of 
Asian adults are obese, with those living in the lowest socioeconomic areas 1.6 times 
more likely to be obese than those living in the highest socioeconomic areas.25 These 
data highlight the social importance of developing effective treatments for the early 
stages of obesity and diabetes. 
1.2 Pathogenesis of Type 2 Diabetes 
Diabetes mellitus is a disorder of impaired metabolism of the macronutrients 
carbohydrate, fat and protein.26 The disease comes in two distinct forms. In both, 
utilisation of glucose decreases, resulting in increased protein and fat metabolism to fuel 
the energy needs of the cell.26 Type 1 is caused by an absolute deficient insulin secretion 
as a result of autoimmune attack on insulin-secreting pancreatic β-cells. The focus of 
this thesis is on Type 2, the most prevalent form of the disease.17, 20 The pathogenesis of 
T2DM is outlined in Figure 1. It involves a combination of insulin resistance and 
relative insulin deficiency. Typically, obesity is the driver of insulin resistance and 
precedes the onset of T2DM, with individuals progressing through an intermediate 
phase of prediabetes where pancreatic insulin production and release becomes impaired 
and blood glucose concentrations begin to rise, before eventually being classified as 
having T2DM. Although the diagnosis of T2DM is based on the development of 
hyperglycaemia, the underlying mechanisms and relative contribution of insulin 
resistance and insulin deficiency are highly variable between individuals. 
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1.3 Current Interventions 
Current treatments throughout the pathogenesis of T2DM are outlined in Figure 1. 
These include lifestyle interventions to promote weight loss such as reducing intake of 
refined carbohydrate and saturated fat, paired with increased physical activity.27 A range 
of pharmacological interventions with diverse mechanisms are used progressively and 
additively as required to control hyperglycaemia. Metformin, which predominantly 
reduces hepatic insulin resistance, is the first line agent. Newer classes of agents such as 
sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-
1) receptor agonists have become increasingly used as evidence mounts for the 
cardiovascular and renal benefits of these pharmaceuticals, and finally insulin 
supplementation may be added in some cases.21, 28, 29 Bariatric surgery may be 
considered and can result in remission of T2DM if implemented early enough in the 
course of the disease.30 Current treatments are broadly effective on an individual 
level,31-33 but the steady increase in obesity and T2DM both nationally and globally 
indicate a need for the development of novel therapeutics in this area. 
 
Figure 1. Current treatment options for pathogenesis of obesity-induced type 2 diabetes 
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1.4 Metabolic Disease and Immunometabolism 
Metabolic disease can be broadly characterised as the inflexibility of an organism to 
adapt to changes in metabolic demand, leading to a disruption in normal metabolism.34 
Immunometabolism is a novel approach to metabolic disease that could be applied as a 
platform of study leading to effective, novel therapeutics. The amalgamation of 
immunity and metabolism has gained traction in the literature over the last decade6 but 
it has been argued that the two processes have been co-evolving over billions of years 
due to the need for efficient protection from external pathogens.7 The idea of 
immunometabolism has two central concepts. The first concept is that cellular 
metabolism, as applied to immune cells, dictates cell function; and the second is the 
theory that immune cells play an integral role in the development and exacerbation of 
metabolic disease.6 To date, immune cells have largely only been studied in the context 
of either the first or second concept, and due to the lack of integration of these, the 
impact of immunometabolism on metabolic disorders remains to be elucidated. 
1.5 Obesity is a Driving Force for Inflammation and Type 2 Diabetes  
Obesity can alter signalling factors which are essential for cellular metabolism and 
homeostasis.35 It contributes to a chronic, low-grade inflammatory state due to the 
secretion of pro-inflammatory cytokines by the immune cells which reside there.36 This 
inflammation contributes to a cycle where obesity and inflammation each exacerbate 
one another and eventually leads to impaired insulin sensitivity, and development of 
T2DM by interfering with metabolic homeostasis.1, 36-40  
Overall, a multitude of factors contribute to the chronic inflammatory state of 
individuals suffering from obesity and obesity-induced T2DM. While it is plausible that 
some degree of acute inflammation is necessary to maintain homeostasis, it is not yet 
known to what degree this is, and at what point it becomes detrimental. Inflammation is 
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controlled by various immunological cells, therefore further research into the immune 
system could provide insight for potential immunometabolic therapeutic targets. 
1.6 The Immune System 
The immune system plays an integral role in eliminating pathogens from the body, and 
is made up of two major parts – innate and adaptive. Innate immunity is typically 
responsible for rapid, non-specific attack on invading pathogens via cytotoxicity, 
phagocytosis, or secretion of antimicrobial peptides or cytokines.41 By contrast, 
adaptive immunity provides a slower, more targeted response, the specificity for which 
is determined by random somatic gene recombination during lymphocyte 
development,42 leading to the generation of a large repertoire of antigen-specific binding 
sites. Effector cells of the adaptive system must first proliferate via clonal expansion, 
generating many individual cells with the same antigen receptor for attack. However 
this process can take between 4 and 14 days,43, 44 which makes the rapid response of 
innate immunity so crucial. 
1.6.1 T Cells 
Thymus matured cells (T cells) are part of the adaptive immune response. 
Predominating types of mature, conventional T cells include effector cytotoxic (Tcyt) 
and helper (Th), expressing CD8 and CD4 respectively, memory (Tm), and regulatory T 
cells (Treg).  
1.6.1.1 Major Histocompatibility Complex (MHC) 
Major histocompatibility complex (MHC),45 is a major signalling protein between the 
two arms of the immune system. Found on the surface of antigen presenting cells 
(APCs) belonging to innate immunity, MHC complexes with antigens, enabling 
presentation to lymphocytes and stimulating the adaptive immune response.46 The two 
classes of MHC are characterised as class I and class II, and the interaction between the 
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MHC-antigen complex at the activation site is stabilised by cluster of differentiation 
(CD) molecules CD8 or CD4 respectively (Figure 2). Typically, T cells are either CD4 
or CD8 positive, however many subsets are double negative for these molecules47 and 
there are accounts of a population of circulating cells expressing both CD4 and CD8.48, 
49 
 
Figure 2. Major histocompatibility complex class I presents antigen to T cell receptor with the 
aid of cluster of differentiation molecule 8.  
Figure created using BioRender 
1.6.1.1.1 T Cell Receptor 
T cell activation occurs via the T cell receptor (TCR), a membrane-spanning protein that 
recognises the antigen-MHC complex of an APC. The classification of TCRs can be 
divided into two distinct heterodimers, expressing either a combination of αβ or γδ 
polypeptides in their variable regions, with the most common being αβ (Figure 3).50 
Once a naïve T cell has been activated by binding of its cognate antigen to its specific 
TCR, it exhibits clonal expansion and differentiation into effector and memory subsets, 
and migrates to the infected tissue to begin clearing the pathogen. 
7 
 
Figure 3. Illustration of the two forms of T cell receptor - ab and gd.  
Figure created using BioRender 
1.6.1.1.2 T Cell Metabolic Profile 
Review articles by Buck et al51 and Shyer et al52 expertly explain the intricately 
interlaced and diverse metabolic pathways influencing and characterising lymphocyte 
fate. The summary of metabolic pathways utilised by immune cells depicted in Figure 4 
was created by Artyomov and Van den Bossche,53 who also describe and review the 
various metabolic pathways. 
 
Figure 4. Key metabolic pathways in immune cells 
Image created by Artyomov and Van den Bossche.53 
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Briefly, naïve T cells are quiescent for extended periods, using fatty acid β-oxidation, 
oxidative phosphorylation (OXPHOS) and pyruvate oxidation to support their basal 
functions.54 Once activated, bioenergetic demand increases as they undergo clonal 
expansion, and metabolic reprogramming stimulates glycolysis, the pentose phosphate 
pathway and glutaminolysis to dominate (Figure 5).55 Tm development is accompanied 
with the switch from glycolysis of effector cell, to fatty acid oxidation (FAO). Indeed, 
triggering FAO by stimulation of adenosine monophosphate-activated protein kinase 
(AMPK) activity through use of metformin promotes Tm cell development.56 
 
Figure 5. Predominating known metabolic pathways utilised by T cells throughout their 
lifecycle.  
Figure created using BioRender. 
Enhanced glycolysis has been found to occur in a number of activated immunological 
cells, including dendritic cells, NK cells, macrophages, and bone marrow matured (B) 
and T lymphocytes.57, 58 This phenomenon of aerobic glycolysis taking place when 
sufficient oxygen is available to support OXPHOS is known as the Warburg effect.59 
Although the yield of the energy molecule, adenosine triphosphate (ATP) generated by 
glycolysis is comparatively lower than that of OXPHOS, it remains an essential 
pathway to produce a multitude of metabolic intermediates which can be shunted into 
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anabolic systems.60 Alternatively, increasing OXPHOS would necessitate generation of 
mitochondria, which is an energetically expensive and time-consuming process.57 
Enhanced aerobic glycolysis therefore enables cells to efficiently generate both a 
sufficient amount of ATP, as well as a number of the required biosynthetic metabolites 
that enable effector function. However, mitochondria do not lay dormant during aerobic 
glycolysis, as was once imagined. Carbon-13 labelling has shown that some pyruvate 
generated by glycolysis is oxidised by mitochondria in human cancer cells,61 similarly 
mice lacking a functional mitochondrial complex III, display impaired activation,62 
indicating that cells utilise both ATP-generating systems during this time.  
1.7 Innate-like T Cells 
Innate-like T cells straddle both innate and adaptive immunity through an alteration of 
the TCR response.8 Specifically, ILT cells express a semi-invariant TCR and are 
restricted by conserved, monomorphic MHC-like molecules.63, 64 Similar to 
conventional T cells, ILT cells mature in the thymus from hematopoietic precursor cells, 
and express T cell marker, CD3.65 ILT gain their ‘innate-like’ title from their rapid 
response upon activation.64, 66 One of the major gaps in ILT cell knowledge is with 
regard to activation. It is known that ILT cells possess the ability to become activated 
from either their TCR, through cytokine signalling, or both, an ability afforded by the 
expression of the ILT-specific transcription factor promyelocytic leukaemia zinc finger 
(PLZF).67 However the effect each method of activation has on cell function, whether 
simultaneous stimulation elicits a different response and the relevance of both for AT 
health and disease, remains to be fully elucidated.64, 66  
The predominant ILT cells in humans are invariant natural killer T (iNKT) cells, 
mucosal associated invariant T (MAIT) cells and γδ T cells, expressing the γ9 and δ2 
TCR chains (Vγ9+Vδ2+ T cells), which are restricted by CD1d, MHC related molecule 
10 
(MR)1 and butyrophilin (BTN)3A1, respectively.68-70 ILT cells and their respective 
antigen presenting molecules are highly conserved between human and mouse, except 
for Vγ9+Vδ2+ T cells and BTN3A1, which only exist in humans.71 Some ILT cells show 
evidence of a memory phenotype, with the cells homing to tissues and lying dormant 
until secondary activation.72, 73 This capability could be beneficial under homeostatic 
metabolic conditions, however if ILT cells are coming into contact with their antigens 
regularly, they could be a contributing factor to the chronic inflammation observed in 
obese AT. 
1.7.1 Invariant Natural Killer T (iNKT) Cells 
iNKT cells are so named due to their expression of the natural killer cell marker, 
NK1.174, 75 as well as their ability to proliferate exponentially upon activation in the 
thymus. iNKT cell TCR are of the αβ variety, expressing an invariant α-chain associated 
with a small repertoire of β chains – in humans Vα24-Jα18 and Vβ11 – and recognising 
lipid antigens bound to CD1d.76 These cells are not to be confused with NKT cells, 
which possess a comparably more variant TCR. α-galactosylceramide (α-GalCer) is the 
prototypical antigen of iNKT cells. Along with iNKT cells exhibiting memory cell 
characteristics, activation induces the rapid release of cytokines, and cytotoxic 
capabilities.10 
Enhanced activity and/or frequency of iNKT cells has been associated with allergic 
asthma,10 alcoholic and nonalcoholic liver disease,77, 78 and ischemia-reperfusion injury 
resulting from sickle cell disease79 in murine models. Increased frequency of activated 
iNKT cells was observed in the circulation of human participants with sickle cell 
disease 80 and nonalcoholic steatohepatitis.78 Conversely, decreased iNKT cell 
frequency in the circulation and spleen of humans has been correlated with human 
herpesvirus 8 and multicentric Castleman disease.81 This contradictory data suggests 
that solely analysing the frequency of iNKT cells in patients should not be used to 
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predict their influence on disease. An understanding of their metabolic demands within 
disease is necessary to be able to utilize them as immunotherapeutic targets. 
NKT cells differ from their conventional CD4+ T cell counterparts in that NKT cells 
metabolise glucose through the pentose phosphate pathway (PPP) and tricarboxylic acid 
(TCA) cycle, as opposed to being converted to lactate via glycolysis.82 In keeping with 
this, a recent study on the metabolic profile of T cells in peripheral blood mononuclear 
cells (PBMC) demonstrated that key metabolites for the TCA cycle and fatty acid 
oxidation were higher in NKT cells than conventional CD4+ T cells.83 Activation in 
iNKT cells is associated with enhanced glycolysis. However, activated iNKT cells also 
demonstrate increased mitochondrial capacity, further confirming that aerobic 
glycolysis and OXPHOS are not mutually exclusive processes.84 Aerobic glycolysis is 
required for optimal iNKT cell interferon (IFN)g production through increased TCR 
recycling,84 but it is not essential for T cell proliferation and survival in general.85 The 
finding of a positive feedback loop via aerobic glycolysis generates a mechanistic link 
between TCR engagement and IFNg release. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) is the key glycolytic enzyme influencing this mechanism. 
When GAPDH is not involved in glycolysis, it acts as a translational inhibitor for IFNg 
mRNA. During glycolysis, it works enzymatically and is therefore not available to 
inhibit IFNg production.85 It is their ability to secrete both anti- and pro-inflammatory 
cytokines that makes iNKT cells a viable potential immunometabolic target. 
1.7.2 Mucosal Associated Invariant T (MAIT) Cells 
Monomorphic MHC class-I related molecule, MR1, presents riboflavin precursors and 
metabolites to a semi-invariant αβ TCR found on MAIT cells. As such, these cells are 
primarily activated by bacteria and fungi, but have also shown activation in response to 
some viral infections.86, 87 Interestingly, activation in response to viral infection is a 
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TCR independent process, and has been shown to occur by interleukin (IL)-18 
signalling together with IL-12, IL-15 or IFN-α/β88 indicating that this group of ILT cell 
also has the capacity to respond to inflammatory signals. MAIT cells tend to reside in 
mucosal tissues, hence their name, but are also found in abundance in human blood, and 
peripheral tissues such as the liver under standard physiological conditions.12, 89 
Combinations of MAIT cell TCR in humans are Vα7.2 joined to Jα33, Jα20 or Jα12, 
and paired with a limited β-chain repertoire.90 MAIT cells were once difficult to target 
in a research setting due to their phenotypic definition being shared with other T cell 
variations. Reantragoon et al solved this issue by developing a tetramer which, when 
bound to a MAIT cell agonist such as 5-(2-oxopropylideneamino)-6-D-
ribitylaminouracil (5-OP-RU), was able to distinguish MAIT cells ex vivo.90 5-OP-RU 
is a potent agonist inducing MAIT cell activation and is therefore a valuable antigen in 
MAIT cell research.91 Upon activation in humans, MAIT cells migrate to infected 
tissues, secrete pro-inflammatory cytokines, including IL-17,63 and exhibit 
cytotoxicity.89 They also show signs of tissue residency and memory potential.92 
PLZF and Microbial colonization are major factors controlling late-stage MAIT cell 
development.93 Environmental bacteria are thought to shape the TCR repertoire of 
MAIT cells and thereby increase their ability to identify cells with bacterial infections.68 
MAIT cell frequency in blood was found to increase from birth, peak between ages 20-
29, and progressively decline with further ageing.94, 95 The cause-effect relationship of 
reduced MAIT cell numbers in blood is currently unclear, however it could be 
associated with increased risk of microbial infection, due to MAIT cells functioning as 
microbial sentinels. 
MAIT cells have been implicated in immune diseases such as multiple sclerosis (MS), 
and inflammatory bowel disease (IBD), with the frequency of MAIT cells in the blood 
decreasing during the progression of MS and increasing during remission.96 Similarly in 
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IBD, the frequency of MAIT cells in blood decreases, and activated MAIT cells 
accumulate in inflamed mucosa,97, 98 indicating a possible role in exacerbation of the 
mucosal inflammation. Additionally, blood-derived MAIT cells from IBD patients 
activated in vitro secreted significantly more IL-17 compared to healthy controls. From 
these findings, it is clear that abnormal MAIT cell proportion in blood and tissues can 
have disease-causing effects. 
1.7.3 Vγ9+Vδ2+ T Cells 
Human γδ T cells are typically categorized according to their TCR Vδ chain. Out of the 
eight functional human Vδ gene segments, the first three, i.e. Vδ1, Vδ2 and Vδ3, are the 
most commonly used in the human γδ T cell repertoire.99 Importantly, Vδ2 is almost 
exclusively paired with Vγ9 and the resulting Vγ9+Vδ2+ T cell population represents the 
largest γδ T cell subset in human blood, and the only one commonly referred to as 
innate-like.99-103 In mice and humans, γδ T cells are particularly enriched in tissue, such 
as AT, as compared to the circulation and lymphoid organs.104 Of particular relevance, 
and in contrast to the compositional bias of blood, Vδ1+, Vδ2+ and Vδ3+ T cells are 
found enriched and reach comparable frequencies in human AT.105 
While the antigen specificity of Vδ2- T cells remains an area of intense investigation, 
Vγ9+Vδ2+ T cells are specifically and exquisitely sensitive to the presentation of 
phosphoantigens, including endogenous prenyl-pyrophosphates, through the MHC-
unrelated molecules BTN3A1 and BTN2A1.106 An increase in host cell intracellular 
phosphoantigen levels is associated with a conformational change in BTN3A1, followed 
by Vγ9+Vδ2+ T cell activation and associated cytolytic and effector functions.107 
Interestingly, these cells have been found in abundance in human fetuses, indicating that 
post-natal pathogenic encounters may not be the sole activator for this cell type.108 
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The clinical relevance of Vγ9+Vδ2+ T cells has for the most part been studied in the 
context of cancer immunology because of Vγ9+Vδ2+ T cells potent ability to recognize 
and kill tumour cells.11, 109 However, Vγ9+Vδ2+ T cells may also play a protective role 
against malaria and other infectious disease,99, 110 due to their ability to recognize 
microbial-derived phosphoantigens.111 
The intrinsic immunometabolic pathways governing Vγ9+Vδ2+ T cell function have not 
yet been studied in any detail. 
1.8 Innate-like T cells in Metabolic Disease Research 
In the context of metabolic disease, ILT cells have largely been studied in isolation, 
with few research studies analysing more than one subtype at a time. One review article 
links MAIT cells to metabolic disease.112 A low proportion of circulating MAIT cells, 
for example, has been implicated in obesity and T2DM, with obese individuals 
harbouring more MAIT cells in their AT compared to healthy controls, implying that 
they have been recruited by a stimulus from the excess AT. Moreover, the MAIT cells 
in AT have an IL-17 profile, and therefore probable inflammatory phenotype.9, 113 
Further research confirmed these findings, concluding that AT resident MAIT cells are 
enriched in people who are obese or have T2DM. The production of IL-17 was 
positively correlated with insulin resistance, while the production of the anti-
inflammatory cytokine, IL-10 appeared to be down-regulated.114 Metabolic disease 
generally appears to correlate with reduced circulating MAIT cells, which adopt a pro-
inflammatory phenotype. This occurs in patients with alcoholic and non-alcoholic fatty 
liver disease, and a number of cardiometabolic disorders.115, 116 Furthermore, MAIT cell 
reduction in peripheral blood has been correlated with increased glycated haemoglobin, 
a symptom of T2DM pathogenesis. Finally, MAIT cells from obese individuals fail to 
substantially increase their rate of aerobic glycolysis upon activation,117 which could 
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interfere with a number of intrinsic metabolic pathways, from deficient cytokine release, 
to mitotic impairment. Indeed, stimulatory cytokine, IFNγ production is impeded as a 
direct result of insufficient aerobic glycolysis during activation.85, 117 
Complementing aspects of ILT cell biology relevant for metabolic homeostasis and 
disease have been addressed in humans and mice, but a unifying picture is lacking due 
to incomplete understanding of functional overlap or redundancy between ILT cells. 
There is some evidence to suggest that iNKT cells play a protective role in metabolic 
disease.118 In particular, the activation of iNKT cells with their prototypical agonist, α-
GalCer, has been shown to support weight loss and glycemic control in mice.119, 120 The 
mechanism of action for this appears to be due in part to iNKT cell activation of 
fibroblast growth factor 21 (FGF21), which led to increased thermogenesis and 
browning of white AT.121 Whether iNKT cell frequency in humans is sufficient to 
promote similar health outcomes, provided their functional role in human disease is 
similar, is currently unknown. Interestingly, FGF21 expression can also be induced by 
GLP-1, a pharmacological agent mentioned previously to treat T2DM pathogenesis.121 
In lean AT, iNKT cells are generally thought to contribute to inflammatory 
homeostasis. In mice, AT residing iNKT cells secrete IL-2 and IL-10.122 Both cytokines 
promote the accumulation of Treg cells, which implies that iNKT cells in healthy models 
modulate immune responses. These cells are also depleted in the omental AT of obese 
individuals,123 which could contribute to the inflamed AT environment. However, there 
remains conflicting data on whether NKT cells in general play a protective or 
pathogenic role in metabolic disease, as mice lacking the iNKT cell TCR unit Jα18 
displayed reduced weight gain and a better metabolic profile compared to wild type.124, 
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Murine AT-resident γδ T cells are described as important mediators of thermogenesis 
and AT homeostasis in mice through their secretion of IL-17,105 but whether human 
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Vγ9+Vδ2+ T cells equally contribute to metabolic homeostasis remains to be 
established. Arguably, this function may be carried out by MAIT cells which, as stated 
previously, have been shown to adopt an IL-17-producing phenotype in people with 
obesity and T2DM. The effect of Vγ9+Vδ2+ T cells was studied in the context of 
osteoporosis, a metabolic bone disease, with data showing increased activity of 
Vγ9+Vδ2+ T cells after the use of bisphosphonates, namely zoledronic acid, both in vitro 
and in vivo.126, 127 Authors indicate Vγ9+Vδ2+ differentiation towards an effector-
memory like phenotype, reducing bone loss. To complement this, a randomized control 
trial involving 60 post-menopausal women with prediabetes and osteopenia who 
received 12 weeks of either 70 mg/week bisphosphonate or a placebo, found a positive 
correlation between the group receiving bisphosphonates and their fasting plasma 
glucose and hemoglobin (Hb)A1c concentration. These clinical data suggest that 
Vγ9+Vδ2+ T cell activation by bisphosphonates may be beneficial for metabolic 
disease.128 In the context of obesity, one study found that when Vγ9+Vδ2+ T cells are 
activated, they take up low-density lipoprotein (LDL), which can be toxic to the cell. As 
the intracellular concentration of LDL increased, Vγ9+Vδ2+ T cells downregulated their 
metabolism, measured by decreased mitochondrial mass, decreased cellular ATP, and 
lower production rates of secreted effector cytokines.129 Therefore, obese individuals 
with a higher proportion of circulating LDL may have impeded functionality of 
Vγ9+Vδ2+ T cells, leading to increased risk of cancer, and potentially other diseases yet 
to be linked to the dysfunction of this ILT cell subtype. 
The predominantly protective effect described so far for iNKT and Vγ9+Vδ2+ T cells in 
obesity and T2DM, which contrasts with the proposed pathogenic role attributed to 
MAIT cells, is reflected in a pilot study recently conducted by Li et al.130 The results 
from this study, the first side-by-side analysis of phenotype and function of human 
blood-derived iNKT, MAIT and Vγ9+Vδ2+ T cells, indicated that iNKT cells and 
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Vγ9+Vδ2+ T cells concomitantly ceased to produce the regulatory cytokines IL-2 and 
IL-4, while MAIT cells secreted larger amounts of IL-17.  
Although the AT microenvironment may provide unique tissue-specific cues and 
stimuli, careful consideration needs to be given to the potentially intrinsic difference 
between circulating and AT resident ILT cells. It is well documented that ILT cell 
development relies on the expression of the transcription factor PLZF, as ILT cells are 
virtually absent in PLZF-deficient mice and humans.131-135 While ILT cells largely 
retain the expression of PLZF in the periphery, AT-resident iNKT cells have been 
shown to express the basic leucine zipper transcription factor, E4 promoter–binding 
protein 4 (E4BP4) instead,122 a phenomenon which may be at least partly due to distinct 
TCR signalling events.136 Whether similar discrepancies exist between circulating and 
AT-resident MAIT and Vγ9+Vδ2+ T cells is currently unknown. In terms of the 
frequencies of the three ILT subsets and their contribution to disease, Magalhaes et al 
find that in the AT of obese participants, there was no significant difference between 
groups.113 
1.9 Spectral Flow Cytometry 
Spectral flow cytometry enables single cell resolution using fluidics. A cell flows 
through a narrow tube to the interrogation site, where a laser is beamed at it, making 
fluorophore-conjugated antibodies attached to their antigens, fluoresce. Spectral flow 
cytometers contain between three and five lasers, with the five-lasers being ultraviolet 
(UV), (355 nm), violet (405 nm), blue (488 nm), yellow-green (561 nm), and red (633 
nm). The fluorescence is picked up by detectors and converted into a digital spectral 
signature. In a five-laser system, there are 64 detectors; 16 in both the UV and violet, 14 
in the blue, 10 in the yellow-green and 8 in the red. Cells can therefore be analysed 
based on expression of the target antigen and, depending on the antigen and panel 
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design, the expression level of the antigen. Compared to conventional flow cytometry, 
spectral flow cytometry gives better resolution, and the ability to increase the number of 
fluorescent tags in the panel, which is achieved because the spectral flow cytometer 
detects the entire spectral range of a fluorophores’ signature, as opposed to a specified 
bandwidth.137 Additionally, spectral flow cytometry utilises an unmixing algorithm, 
allowing fluorophores in a mixed sample to be distinguished.138 
1.9.1 Clones 
When used in the context of cytometry, a clone refers to the isolated B cell which 
generated a particular antibody against a target antigen. The most common technique is 
the hybridoma technique. Using this technique, first the target antigen is injected into a 
recipient animal such as a mouse, rat, rabbit, or sheep. B cells within the animal vessel 
generate a varied assortment of antibodies against the antigen, each B cell generates an 
antibody which targets a slightly different epitope. The B cells are then isolated from 
the animal, fused in vitro with immortal myeloma cells and separated and expanded into 
colonies, thus all cells generate an antibody targeting the same epitope.139 Antibodies 
developed in this way are termed monoclonal. Polyclonal antibodies are a mixture of 
antibodies all against the same antigen, but not all from the same B cell. These will 
recognise a range of epitopes and are therefore more resistant to changes in the antigen 
such as heterogeneity or glycosylation. 
1.10 Metabolic Flow Cytometry (Met-Flow) 
The metabolic flow cytometry (Met-Flow) methodology, first described by Ahl et al, is 
an extremely novel technique for high-dimensional profiling of a heterogeneous sample 
of immune cells using spectral flow cytometry.83 The ability to characterise 
metabolically distinct immune cell lineages by single cell metabolic profiling was also 
characterised by Hartmann et al.140 The technique targets key proteins from discrete 
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metabolic pathways to determine the anabolic and catabolic reactions within a single 
cell, thus helping to define metabolic state. Ahl et al successfully demonstrate, using 
Met-Flow, the metabolic switch in individual T cells upon activation, notably, increased 
expression of proteins involved in glycolysis, OXPHOS and FAO, outlining the 
intertwined nature of metabolic reprogramming and T cell activation.  
When planning for the project outlined in this thesis began, the only available 
manuscripts detailing the Met-Flow technique were in bioRxiv (bio-archive) and had 
not been peer-reviewed,140, 141 thus reinforcing the pioneering nature of this work. 
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Hypothesis, Aim, and Objectives 
2.1 Hypothesis 
The hypothesis that we are working towards testing is that in healthy people, i.e with no 
metabolic disease, the frequency and function of iNKT, MAIT and Vγ9+Vδ2+ T cells in 
peripheral blood will be similar to their frequency and function in AT. 
2.2 Aim 
The original aim of the research project was to use the Met-Flow methodology to test 
the above hypothesis by assessing the frequency and function of ILT cells in AT of 
metabolically healthy human participants and compare it to that of the same 
participants’ peripheral blood ILT cells. The justification for which is to aid in 
understanding of ILT cell immunometabolism in AT and peripheral blood, to inform 
whether peripheral blood can be used as a surrogate for AT in future studies, 
particularly intervention studies with the hypothesis that ILT cells can be targeted 
therapeutically to improve weight and metabolic outcomes.  
However, due to the circumstances and impact of COVID-19, AT became impossible to 
procure as elective surgeries were cancelled, and access to the laboratory and sourcing 
consumables from overseas severely impeded, and in some instances impossible. 
Therefore, the aim of the project was modified to designing a Met-Flow based panel 
which allows for the identification and phenotype recognition of the three major subsets 
of ILT cells in metabolically healthy individuals, determined by HbA1c analysis, with 
the goal of using the data to construct a metabolic profile for ILT cells in peripheral 
blood, and to build upon previous metabolic disease research to provide insight into the 
role(s) of ILT cells in the dialogue between cellular and organismal metabolism. The 
panel would allow for high throughput research into the metabolism of these cells, and 
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provide a foundation of research to be transferred to AT when it becomes an available 
resource –enabling the original hypothesis to be tested. 
2.3 Objectives 
The main objective of this COVID-19-amended project was: 
To design and optimise a panel for use on a spectral flow cytometer targeting lineage 
markers for cell identification, and specific metabolites in various metabolic pathways, 
as well as expression of transcription factors and key signalling molecules, allowing a 
metabolic profile for human innate-like T cells to begin to be established. 
Specifically to: 
1. Draw peripheral blood from 10 informed, healthy participants 
2. Analyse HbA1c concentration of each participant to confirm metabolic health 
3. Isolate PBMC from whole blood 
4. Design and optimise a panel for use on a spectral flow cytometer 
5. Run the optimised panel on the spectral flow cytometer 
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Materials and Methods 
An overview of the key steps with corresponding methods section is shown in Figure 6. 
 
Figure 6. Key steps in developing spectral flow cytometry panel 
3.1 Ethical Approval 
Ethical approval was obtained from the Health and Disability Ethics Committee 
(HDEC) to draw blood from adults who were part of the Malaghan Institute of Medical 
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Research (MIMR) organisation. In anticipation that the original hypothesis of this 
project would have gone ahead as planned, prior to the COVID-19 pandemic I wrote, 
submitted and received HDEC ethical approval for investigating ILT cells in AT, which 
will be used in the near future. Evidence of this can be viewed in Appendix 1. 
3.2 Participant Recruitment 
An email was sent to all MIMR staff members detailing the study, and requesting 
volunteers. Inclusion criteria were that all participants were adults (aged 18 or older) 
who were willing and able to give written informed consent, and had a self-reported 
body mass index (BMI) between 18 kg/m2 and 35 kg/m2. Exclusion criteria was anyone 
with a current active infection, known malignancy other than basal squamous cell 
carcinoma of the skin, autoimmune diseases including rheumatoid arthritis, systemic 
lupus erythematosus, inflammatory bowel disease, celiac disease, pancreatitis or other 
malabsorption condition, type 1 or type 2 diabetes mellitus, cardiovascular disease, 
previous or current use of bisphosphonates, or current use of steroids or 
immunosuppressants. 
3.3 Sample Collection 
Up to 90 mL whole blood was drawn from each participant by a person trained in 
phlebotomy, into 10 mL Becton Dickinson (BD) Vacutainers® with interior coated 
spray-dried dipotassium ethylenediaminetetraacetic acid (K2EDTA) and transported at 
room temperature (RT). Each vacutainer was gently inverted 8 to 10 times to ensure 
even mixing of K2EDTA with the blood. 
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3.4 HbA1c Analysis 
3.4.1 Whole Blood Processing for HbA1c 
In a sterile cell culture hood, 2 mL was pipetted out of one of the vacutainers containing 
whole blood plus K2EDTA and divided equally into four 1.5 mL Eppendorf® tubes at a 
volume of 500 µL per tube. Tubes were frozen in a -80°C freezer at MIMR. 
Aliquots of whole blood were transported from MIMR to the University of Otago 
Wellington (UOW) on ice, in a private vehicle, and stored immediately at -80°C. 
3.4.2  HbA1c Analysis 
Whole blood from was thawed from -80°C at RT. HbA1c testing was performed using 
the Roche COBAS C311 analyser at UOW as per manufacturer’s instructions.142 
Samples were diluted in haemolyzing reagent in a 1:101 volume by volume (v/v) ratio 
prior to testing. Quality control samples were run simultaneously using the same ratio as 
the patient samples. All samples were run in duplicate.  
3.5 PBMC Isolation and Freezing 
PBMC isolation was achieved by lymphoprep density gradient using SepMate™ tubes. 
SepMate™ tubes contain a physical insert which prevents mixing of the sample and the 
density gradient. This method is more efficient than a typical lymphoprep density 
gradient protocol because the centrifuge can have the brake applied, for example, 
traditional protocols require centrifugation at 400 x g for 20 minutes (min)143 with no 
brake applied. Due to the physical barrier in the SepMate™ tubes, the blood layering 
process is faster and less care is required when aspirating the plasma and buffy coat. 
Overall, SepMate™ tubes utilise knowledge of density gradients to allow for simpler, 
more convenient PBMC isolation. 
Whole blood was poured from the K2EDTA vacutainer into a 50 mL sterile 
polypropylene conical centrifuge Falcon® tube and diluted in a 1:1 (v/v) ratio with 
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Dulbecco's phosphate-buffered saline (DPBS) supplemented with 2% fetal bovine 
serum (FBS) (Gibco by Life Technologies™) which had been heat inactivated at 50°C 
for 30 min. Tubes were mixed gently by inversion. Diluted blood was layered on top of 
15 mL Lymphoprep™ solution (STEMCELL™ Technologies) in a SepMate™-50 tube. 
SepMate™-50 tubes were centrifuged at 1,200 x g for 10 min at RT (acceleration: 9, 
deceleration: 9) in a Heraeus Multifuge X3R centrifuge with a TX-1000 swinging 
bucket rotor (Thermo Fischer Scientific) to separate out the various blood components. 
The crude fraction, containing PBMC and plasma, was poured into a new sterile 50 mL 
Falcon® tube and centrifuged at 760 x g for 8 min at RT (acceleration: 9, deceleration: 
9). The supernatant was discarded by pouring to remove plasma and residual 
Lymphoprep™. PBMC pellet was washed by gently resuspending in 10 mL DPBS-
2%FBS and centrifuged at 300 x g for 8 min at RT (acceleration: 9, deceleration: 9). 
Supernatant was aspirated off. The cell pellet was resuspended in freezing medium, 
made of FBS containing 10% CytoPur™ dimethyl sulfoxide (DMSO) (OriGen 
Biomedical). The volume of freezing medium varied depending on the yield of whole 
blood obtained from each participant, with every 10 mL whole blood equating to 
500 µL freezing media. Cells were pipetted into sterile cryovials at a volume of 500 µL 
per vial. Cryovials were placed in a CoolCell® FTS30 freezer container, and frozen in a 
-80°C freezer overnight before being transferred to liquid nitrogen storage. 
3.6 Spectral Flow Cytometry 
A Cytek® Aurora 5-laser spectral flow cytometer was used to analyse the isolated 
PBMC populations.  
3.6.1 Panel Design 
The aim of the study was to design and optimise a panel for use on a spectral flow 
cytometer targeting lineage markers for cell identification, and specific metabolites in 
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various metabolic pathways, as well as expression of transcription factors and key 
signalling molecules. The panel was designed using the protocol outline by Ferrer-Font 
et al.144 (Figure 7). 
 
Figure 7. Step-by-step protocol for spectral cytometry panel design 
Image taken from Ferrer-Font et al.144 
3.6.1.1 Selection of Target Markers 
A summary of antigens, or markers, used in the panel and their associated fluorophores 
is outlined in Table 1. A comprehensive antibody list including catalogue and lot 
numbers is outlined in Appendix 2. Specifically, Zombie near infrared (NIR)™ was 
used to determine cell viability as it infiltrates the porous membranes of dead and dying 
cells, allowing exclusion of these populations.145 Lineage markers were selected first as 
they allow for identification of cell type. These were determined based on standard 
practises for flow cytometry, and previous protocols from members of MIMR. 
Antibodies against CD3 and CD19 were used to differentiate T cell populations from B 
cell populations, respectively. Markers used to identify the various types of T cells 
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include antibodies for: TCR Vα24-Jα18, and TCR Vg9 and Vd2 to identify iNKT, 
Vg9+Vd2+ cells respectively. The 5-OP-RU loaded MR1 tetramer was used to identify 
MAIT cells. This technology was developed jointly by Dr. James McCluskey, Dr. Jamie 
Rossjohn, and Dr. David Fairlie, and the material was produced by the national institute 
of health (NIH) Tetramer Core Facility as permitted to be distributed by the University 
of Melbourne.146 Additionally, antibodies against CD4 and CD8 were used to identify 
conventional Th and Tcyt cell populations, respectively. Readout antigens were decided 
next. These included activation molecules, transcription factors, cytokines and 
metabolites which were differentially localised to either the mitochondria, the cytosol or 
the cell membrane. Glucose transporter 1 (GLUT1) is a transmembrane glucose 
transporter protein also used by Ahl et al83 to assess changes in glucose entry into the 
cell. Citrate synthase (CitSyn) is an enzyme, located in the mitochondrial matrix, 
catalysing the first reaction of the TCA cycle and was therefore selected to represent 
TCA activity. PLZF is a transcription factor regulating many genes in innate and innate-
like immune cells.147 It has been known to affect effector function of ILT cells148 and 
thus was included in the panel. CD26 is an ectoenzyme located on the surface of a 
variety of cell types, with multifunctional effects.149 On immune cells, CD26 inactivates 
soluble factors, and acts as a co-stimulatory molecule.150 MAIT cells have been 
described as expressing high amounts of CD26,151 however its function with regard to 
MAIT cell activity remains unknown. CD26 is also a target of current metabolic disease 
therapeutics by using inhibitors to block its enzymatic action,152 making it a highly 
relevant metabolic marker in the panel. The cytokines selected in the panel reflect the 
metabolic output of the cells. IL-4 is a regulatory cytokine typically produced by iNKT 
cells, IL-17 is an inflammatory cytokine typically produced by MAIT cells, and IFNg is 
an inflammatory cytokine released by all three subsets of ILT cell. 
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Table 1. Antibodies used for flow cytometry analysis 
 
3.6.1.2 Assigning Fluorophores to each Marker 
Fluorophores, also referred to as colours, were assigned to each marker based on two 
major factors, the first being density of the antigen being targeted. Fluorophore 
brightness and antigen density should be inversely correlated.144 Therefore, bright 
fluorophores are conjugated to antibodies which bind to low density antigens, and vice 
versa, so that the machine can visualise rare antigens, and not be saturated by the 
brightness of highly expressed antigens. The second factor determining fluorophore 
conjugation was the similarity of spectral signatures. Fluorophores with very similar 
spectral signatures cannot be conjugated to co-expressed antigens because the software 
will have difficulty distinguishing the two. Although spectral flow cytometry is superior 
to conventional flow cytometry in the number of fluorophores that it can distinguish 
between, there remains a certain degree of spread between fluorophores which have 
very similar spectral signatures, particularly when the fluorophores are conjugated to 
antibodies whose targets are co-expressed. As it can be difficult to know the expression 
Antigen Fluorophore Clone Control Supplier Dilution Location Purpose
Core Panel
- Zombie NIR - Cells BioLegend® 1:2000 Cell surface Viability
CD3 BV510 UCHT1 Beads BioLegend® 1:100 Cell surface Pan T cell
CD19 BB515 HIB19 Beads BD Horizon™ 1:50 Cell surface Pan B cell
Vα24-Jα18 PE 6B11 Beads BioLegend® 1:25 Cell surface iNKT cell
MR1 tetramer BV421 - Cells NIH 1:800 Intracellular MAIT cell
TCR Vγ9 APC B3 Beads BioLegend® 1:200 Cell surface Vγ9+ T cell
TCR Vδ2 PerCP-Cy5.5 B6 Beads BioLegend® 1:50 Cell surface Vδ2+ T cell
PLZF PE-CF594 R17-809 Beads BD Horizon™ 1:200 Intracellular PLZF activity
GLUT1 AF594 EPR3915 Beads Abcam 1:200 Cell surface Glucose transport
IL-4 PE-Cy7 MP4-25D2 Beads BioLegend® 1:300 Intracellular Immune regulation
IL-17 BV711 BL168 Beads BioLegend® 1:50 Intracellular Inflammation
IFNγ eFluor450 4S.B3 Cells eBioscience 1:200 Intracellular Inflammation
Additions
Citrate Synthase AF647 EPR8067 Beads Abcam 1:100 Mitochondrial 
matrix
TCA cycle activity
CD4 BV605 OKT4 Beads BioLegend® 1:50 Cell surface CD4+ T cell
CD8 BUV395 RPA-T8 Beads BD Horizon™ 1:100 Cell surface CD8+ T cell
CD26/DPP4 BUV496 M-A261 Cells BD Optibuild™1:200 Cell surface Immune activity
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levels of some metabolites, it is possible that high levels of one antigen could cause 
fluorophore spread into another and obscure the true expression intensity of both. To 
mitigate this issue, antibodies for readout antigens were paired with fluorophores that 
had little similarity where possible. Understanding the biology of the target antigens 
was critical for this step. 
3.6.2 Processing of PBMC for Spectral Flow Cytometry Analysis 
PBMC were thawed in a 37°C water bath and washed by addition of 8 mL Iscove's 
Modified Dulbecco's Medium (IMDM) plus glutamax (Gibco by Life Technologies™) 
followed by centrifugation at 600 x g for 4 min at RT. Supernatant was discarded by 
pouring, and 1 µL of Benzonase® Nuclease (Sigma-Aldrich) was added to the 
remaining volume to prevent cell clumping. The Benzonase® was gently pipetted up 
and down to mix and incubated for 5 min. PBMC were then washed with 5 mL IMDM, 
centrifuged at 600 x g for 4 min at RT, and resuspended in media (Table 2).  
Table 2. Media recipe 
 
3.6.3 Cell Counting via Trypan Blue Exclusion 
Briefly, 10 µL sample was mixed with 10 µL Trypan Blue Stain 0.4% (Gibco by Life 
Technologies™) which had been diluted 1:4 (v/v) with PBS. After which, 10 µL of the 
stained cells was loaded beneath the glass coverslip of an improved Neubauer bright-
line double-ruling haemocytometer. An Olympus CX41 microscope was used to view 
and count viable cells. 
Concentration Reagent Supplier
IMDM plus Glutamax Gibco® by Life Technologies™
2 mM L-glutamine Gibco® by Life Technologies™
1% Non-essential amino acids Sigma-Aldrich
1% Sodium pyruvate Gibco® by Life Technologies™
1% Penicillin/streptomycin Gibco® by Life Technologies™
10 µM 2-Mercaptoethanol Gibco® by Life Technologies™
5% Human male AB normal serum Sigma-Aldrich
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Cells were plated at a volume of 200 µL in a 96-well round-bottom tissue culture plate 
at a density ranging between 5 x 105 to 1.5 x 106 cells/well for optimisation 
experiments. Cells were plated more densely for the final run to ensure that rare 
populations would be picked up as there were issues with this during optimisation. For 
the final run, cells were plated at 3 x 106 cells/well in a volume of 222 µL. 
3.6.4 In vitro Stimulation of PMBC 
For non-specific stimulation, PBMC were stimulated by addition of phorbol myristate 
acetate (PMA) (Sigma-Aldrich), and ionomycin (Sigma-Aldrich) to media. 
Concentration of stimulants and length of stimulation varied as the panel was being 
optimised and is therefore outlined in the appropriate section. 
3.6.5 Staining 
Prior to staining, all fluorophores were centrifuged in their stock tubes at 14,000 x g at 
RT for 2 min to pellet fluorophore aggregates. All subsequent centrifugation steps were 
carried out at 940 x g for 2 min at 4°C, and supernatant was discarded after each 
centrifugation by careful flicking of the plate unless otherwise stated. Wash steps 
involve addition of the specified wash buffer, centrifugation at the aforementioned 
conditions, and then discarding the reagent. For list of staining antibodies, refer to Table 
1. 
To mitigate staining artefacts caused by BD Horizon Brilliant™ fluorophores, when 
more than two brilliant™ dyes were used in the staining mix, one-fifth of the volume of 
the antibody staining mixture was made up of Brilliant Stain Buffer Plus (BD 
Horizon™). 
3.6.5.1 Viability Stain 
Following stimulation, PBMC were centrifuged and then washed with 200 µL PBS. 
PMBC were stained using Zombie NIR™ diluted in PBS for 15 min at RT in the dark. 
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PBMC were centrifuged and then washed in 200 µL fluorescence-activated cell sorting 
(FACS) buffer (Table 3). 
Table 3. FACS buffer recipe 
Concentration Reagent Supplier  
PBS Gibco by Life Technologies™ 
5% FBS Gibco by Life Technologies™ 
2 mM EDTA Invitrogen by Life Technologies™ 
   
3.6.5.2 Fragment Crystallisable (Fc) Region Blocking 
Fragment crystallisable (Fc) region was blocked by addition of 50 µL of a 1:40 dilution 
of Human TruStain FcX™ (Fc Receptor Blocking Solution) (BioLegend®) in FACS 
buffer to all wells, followed by a 10 min incubation period on ice, in the dark. From this 
point on, all subsequent steps until addition of intracellular antibody stain were carried 
out on ice. Incubation was followed by addition of 150 µL FACS buffer and 
centrifugation. A wash step was then carried out using 200 µL FACS buffer. 
3.6.5.3 Cell Surface Stain 
Antibodies targeting markers located on the cell surface were prepared in FACS buffer, 
and Brilliant Stain Buffer Plus (BD Horizon™) where appropriate. Concentration of 
some antibodies varied throughout the optimisation of the panel and is therefore 
outlined in the optimisation section. Optimised antibody dilutions are outlined in Table 
1. To stain, 50 µL of the antibody staining solution was pipetted into the corresponding 
wells. 
3.6.5.4 Fixation and Permeabilisation 
Cells were fixed by cross-linking and permeabilised to allow entry of cell-impermeable 
fluorophore-conjugated antibodies for intracellular staining. The 96-well plate was 
vortexed briefly to avoid cell aggregation, and cell pellets were resuspended in 150 µL 
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Fixation/Permeabilization solution from a BD Cytofix/Cytoperm™ 
Fixation/Permeabilization Solution Kit (BD Biosciences). PBMC were incubated for 20 
mins on ice, in the dark and then centrifuged. PBMC were then washed by addition of 
150 µL 1x BD Perm/Wash™ Buffer from the same kit. 
3.6.5.5 Intracellular Staining 
To the cell pellet, 50 µL of 1x BD Perm/Wash™ Buffer containing antibodies targeting 
intracellular located markers was added to the corresponding wells and incubated for 30 
min at RT in the dark, followed by addition of 100 µL 1x BD Perm/Wash™ Buffer. 
PBMC were centrifuged and then washed with 200 µL FACS buffer to close the 
permeabilised membranes. FACS buffer was then used to transport the cells to 
individual spectral flow cytometer tubes by first resuspending in 100 µL FACS buffer 
and moving to the corresponding tube, then addition of a further 100 µL FACS buffer to 
the well to ensure all cells were taken. 
Spectral flow cytometer tubes were covered with aluminium foil and stored at 4°C 
overnight for analysis the following day. 
3.6.6 Panel Optimisation 
The panel was optimised at the cytometer. Optimisation is crucial for high-dimensional 
analysis using spectral flow cytometry. The four steps to panel optimisation are outlined 
in this section. These include: determining the appropriate concentrations to use for 
each of the antibodies, determining appropriate controls for unmixing, assessing 
compensation matrix, and finally assessing staining resolution and negative population 
spread. A core panel of twelve antibodies was optimised first before four additional 
antibodies were incorporated to generate a working panel containing 16 antibodies in 
total. 
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3.6.6.1 Antibody Titration 
Determining the appropriate concentration of antibody was primarily accomplished by 
reading protocols and according to established laboratory protocols. Where it was not 
possible to determine it in these ways, a titration experiment was run. The primary task 
for titrations is to reach antibody saturation, the point at which all of the antigens have 
bound an antibody. Further addition of antibody past saturation point will increase false 
positives due to non-specific binding. An antibody concentration that is too dilute will 
provide low resolution between the positive and negative populations, and could lead to 
false negatives.  
Titrated antibodies include GLUT1 (AF594) and CitSyn (AF647). Titration 
concentrations were decided upon based on published data,83 and adding concentrations 
to either side to take into account differences in staining resulting from protocol 
differences and flow cytometer sensitivity. GLUT1 and CitSyn antibodies were the 
same stock concentration. Dilution of stock antibodies and their corresponding 
concentrations is outlined in Table 4. 
Table 4. Dilution concentrations for titrating GLUT1 and citrate synthase antibodies 
Dilution 1:750 1:500 1:200 1:100 1:50 
Concentration (µg/mL) 0.67 1 2.5 5 10 
      
3.6.6.1.1 Intracellular Staining for Citrate Synthase 
PBMC were either stimulated for 1 hour (h) in media containing PMA/ionomycin 
(50 ng/mL and 1 µg/mL, respectively) or left unstimulated by incubation in media 
(Table 2) at 37°C supplemented with 5% carbon dioxide (CO2). The staining protocol 
was then followed so that CD3 and CD19 were added as cell surface markers to 
differentiate T cells from B cells (dilutions of these antibodies is outlined in Table 1). 
The CitSyn antibody was added in increasing concentration to cells (Table 4) following 
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the intracellular staining procedure. Additionally, a fluorescence minus one (FMO) 
control group received only the CD3 and CD19 stain. FMO are valuable tools in flow 
cytometry, as they contain the all antibodies being used minus one, which allows for 
more accurate gating during analysis, and gives confidence that stained populations are 
real, as opposed to artefacts arising from errors in staining or compensation. 
3.6.6.1.2 Cell Surface Staining for GLUT1 
PBMC were either stimulated for 1 h in media containing PMA/ionomycin (50 ng/mL 
and 1 µg/mL, respectively) or left unstimulated in media. Incubation conditions were at 
37°C supplemented with 5% CO2. The staining procedure was followed, and CD3 and 
CD19 antibodies were added as cell surface markers to differentiate T cells from B cells 
(dilutions of these antibodies is outlined in Table 1). The GLUT1 antibody was added as 
a cell surface antibody in increasing concentration to cells (Table 4), following the 
staining procedure. An FMO group received only the CD3 and CD19 stain. The same 
protocol was followed after a 48 h stimulation in half the concentration of 
PMA/ionomycin (25 ng/mL and 0.5 µg/mL, respectively). 
3.6.6.1.3 Intracellular Staining for GLUT1 
The clone used to produce the GLUT1 antibody (EPR3915) was producing antibodies 
with a binding region on a transmembrane portion of the GLUT1 protein. As this 
location was closer to the cytosol than the extracellular space, we hypothesized that the 
poor signal was due to the antibody failing to bind. PBMC were therefore treated the 
same as above, with the GLUT1 antibody added as an intracellular antibody. An FMO 
group received only the CD3 and CD19 cell surface stain.  
3.6.6.2 Determining Appropriate Controls for Spectral Unmixing 
Controls are a crucial element of flow cytometry as they allow the machine to analyse 
the spectral signature of each fluorophore, enabling identification of that fluorophore in 
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a heterogeneous fully stained sample. Unmixing was achieved using BD™ CompBeads 
(BD Biosciences) where possible. CompBeads are manufactured polystyrene beads 
containing many Fc regions, and therefore bind any antibody. CompBeads are much 
easier to work with compared to cells as they do not require the same standard of care as 
cells, and they give reliable results. However it is important to first ensure that the 
spectral signature that the beads emit for each fluorophore is the same as what the cells 
of interest emit, so that the machine is detecting the correct signature for each 
fluorophore in the PBMC sample. Where unmixing using CompBeads was not possible, 
PBMC were used. To determine whether CompBeads or PBMC were the most 
appropriate control for each antibody in the panel, both cells and CompBeads were 
stained with each fluorophore individually, and the similarity of the signatures obtained 
were compared. If the median fluorescence intensity (MFI) of the signatures was the 
same or very similar, CompBeads were used. 
To prepare CompBeads for each fluorophore, one drop of CompBeads was added to a 
well of a 96-well plate during cell preparation, after addition of the viability stain and Fc 
block. Each fluorophore-conjugated antibody used in the panel was pipetted into a well 
containing CompBeads at the time of addition of the corresponding antibody to the 
cells, and at the same concentration (Table 1). Both PBMC and CompBeads were 
stained singularly with each antibody, in separate wells, and the MFI of the spectral 
signature for each was calculated using Spectroflo® and Microsoft Excel™ software. 
3.6.6.2.1 Median Fluorescence Intensity 
The MFI for each fluorophore was determined using SpectroFlo® software. First, each 
single stain was assessed using a histogram with the X-axis set to the detector in which 
that particular fluorophore peaked. This allowed for the best visualisation and separation 
of the positive and negative peaks. A positive gate was drawn onto the point of brightest 
intensity of the positive population. A negative gate was drawn over the negative 
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population. The spectral signature of the positive population was visually checked 
against the Cytek™ Fluorochrome 5-Laser Guide,153 to ensure that the correct antibody 
had been used, and contamination was assessed by briefly dragging the positive gate 
over the negative population and checking the spectral signature for patterns from 
another antibody. The MFI of each of the 64 detectors in the 5-laser Aurora™ was 
calculated using the statistics function in SpectroFlo®, and exported to a Microsoft 
Excel™ spreadsheet. This process was followed for both cells and beads for each 
antibody. 
3.6.6.2.2 Normalised Spectrum Overlay of Cells And Beads 
The difference between the positive and negative MFI for each detector was calculated 
in Microsoft Excel™ by subtracting the MFI of the negative gate from the MFI of the 
positive gate. The value of the detector with the maximum difference, i.e. the peak 
channel, was used to normalise the data. Normalisation was achieved by dividing the 
difference between the positive and negative MFI for each detector, by the value of the 
peak channel. The normalised data for each detector, for each fluorophore was plotted 
on a line graph. Cells and beads were overlayed to visually assess similarity. 
3.6.6.3 Assessing Fluorophore Spread for Compensation 
NxN plots for each fluorophore were drawn using SpectroFlo®. These had been 
unmixed using the appropriately determined control, and were gated on viable cells 
(Figure 8A-D). The plots were visually assessed to ensure that the positive population 
for each fluorophore was perpendicular to the other fluorophores. Curvature of a 
population indicated a compensation issue. If this was the case, and beads had been 
used as the control for unmixing, unmixing was attempted again using cells as the 
control. Other methods of mitigating compensation issues include ensuring that the 
controls used for unmixing were brighter than the sample, checking for 
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autofluorescence interference, or manually compensating by dragging populations to the 
correct position. 
3.6.6.4 Assessing Staining Resolution and Negative Population Spread 
Using FlowJo™v10 software, the fluorescence of the fully stained PBMC sample was 
compared to each single stain PBMC sample. Single stain and full stain samples were 
overlayed either on a histogram or dot plot. Spread of the negative population was 
visually compared between single stain and full stain samples to assess the likelihood of 
false positives in the full stain of the final panel. i.e. the negative population of the full 
stain should be as tight or tighter than the negative population of the single stain. 
Once the core panel was sufficiently optimised, additional antibody markers were 
incorporated. The optimisation process was followed for each additional marker. 
3.7 Run of Optimised 16 Colour Panel 
Upon completion of previous steps to design an optimise the panel containing 16 
colours (Table 1), the panel was run on PBMC samples from 10 participants. A 6 h 
stimulation was accomplished using PMA/ionomycin (50 ng/mL and 1 µg/mL, 
respectively) at 37°C supplemented with 5% CO2. Unstimulated cells were 
supplemented with media. After 1 h a Golgi block was used to prevent cytokine release 
into the media. Brefeldin A (10 µg/mL, Sigma-Aldrich) and monensin (0.3 µg/mL, 
Sigma-Aldrich) were added to the media of both stimulated and unstimulated cells. 
Total volume per well was 222 µL. 
Following stimulation, a small proportion of cells were pipetted out of the wells to 
create a pooled population of the stimulated and unstimulated cells for each participant, 
which were used as unstained control cells, controlling for variation in PBMC 
autofluorescence between individuals. A further small proportion of cells were pipetted 
out of each well to create pooled populations containing all participant samples, which 
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were used for single stain cells and FMO controls. FMO controls were run for the 
following markers: GLUT1, CD26, Vα24-Jα18, MR1, IFNg, PLZF, IL-4, and IL-17. 
Data files (.FCS) containing previously run CompBead controls from the optimisation 
phase of the project were imported into SpectroFlo® software at the time of running the 
cells on the machine. This meant that CompBeads did not have to be stained again for 
the final run. 
3.8 Data Analysis and Gating Strategy 
Raw data was analysed using Spectroflo® software and .FCS files were exported and 
analysed using FlowJo™ version (v)10 where gates were applied to scatter plots. To 
exclude doublets, gates were drawn based on the forward-scatter (FSC)-height and 
FSC-area, followed by side-scatter (SSC)-height and SSC-area. The lymphocyte 
population, or cells of interest, was then gated on by plotting SSC-area against FCS-
area. Viable cells were then gated on by plotting SSC-area against Zombie NIR™ and 
drawing a gate around the negative population. T cells were gated on by plotting CD19 
against CD3 and drawing a gate around the CD19-, CD3+ population. Numerical data 
was exported from FlowJo™ into GraphPad Prism (v8) software, and analysed using 
either a paired Student’s t-test or two-way ANOVA with post-hoc Sidak’s multiple 
comparisons test as appropriate, and graphed to illustrate. P values < 0.05 were 




Figure 8. Gating Strategy to identify live T cell population 
A-B: Doubles are excluded using forward scatter height (FSC-H) and area (FSC-A), and then side scatter 
height (SSC-H) and area (SSC-A) plots. C: Lymphocyte population was identified based on their SSC-A 
and FSC-A properties. D: Dead and dying cells are excluded by gating on the Zombie NIR™ negative 
population. E: T cells are distinguished from B cells by plotting CD19 against CD3 and identifying the 





























All participants had an HbA1c below 40 mmol/mol. The mean was 32.7 (standard 
deviation 3.051) with a range of 29 mmol/mol to 38 mmol/mol. Results were quality 
controlled (Table 5). 
Table 5. HbA1c results 
 
4.2  Titrations 
4.2.1 Citrate Synthase Titration 
CitSyn was stained for using the intracellular staining protocol due to its location in the 
mitochondrial matrix. Gating strategy outlined in Figure 8 was followed. The results for 
each concentration were first down-sampled to contain 35,000 events, and then 
concatenated into a dot plot using FlowJo™v10 (Figure 9). The most appropriate 
concentration of 5 µg/mL was determined by visual assessment based on minimal 
spread of the population. The 10 µg/mL concentration could also have been selected, 
however this would not have afforded a much tighter population, and would have 
















Figure 9. Citrate synthase titration 
Human PBMC were either A: Unstimulated, or B: stimulated with PMA/ionomycin (50 ng/mL and 
1 µg/mL, respectively) for 1 h. After which, PBMC were stained intracellularly with increasing 
concentration of an AF647 fluorophore conjugated antibody against the citrate synthase (CitSyn) enzyme, 
in the same staining volume. Fluorescence minus one (FMO) does not contain any antibody against 
citrate synthase. All treatments also contain cell surface antibodies against CD3 and CD19 to allow for T 
cell specific gating. Data measured by spectral flow cytometry and analysed using FlowJo™v10. Red box 
indicates the selected concentration of antibody. 
4.2.2 GLUT1 Titration 
4.2.2.1 Cell Surface Stain 
GLUT1 was stained using a cell surface staining protocol based on previous laboratory 
group recommendations, and the literature.83 There was no clear difference between the 
stimulated and unstimulated groups, and there was also no clear positive population to 
gate on (Appendix 3, Figure S1). 
4.2.2.2 Intracellular Stain 
Based on the poor binding of GLUT1 in the previous experiment, the epitope of the 
GLUT1 antibody was investigated further. It was found to bind to a transmembrane 
portion of GLUT1 which was closer to the cytoplasmic side of the protein. For this 
reason, and to test whether the antibody was functional, GLUT1 was stained using the 
intracellular procedure. 
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There was a clear visual difference between the fluorescence intensity of GLUT1 
stained on the cell surface compared to intracellular (Appendix 3, Figure S1 and Figure 
S2), although the stimulation did not appear to influence the amount of GLUT1 staining 
significantly (Appendix 3, Figure S2). The amount of GLUT1 stained intracellularly 
seemed to increase with increasing antibody concentration, however because there was 
no discernible positive and negative population, no conclusion was made as to whether 
this was a true increase in staining, or an increase in non-specific binding of the 
antibody.   
4.2.2.3 Cell Surface Stain – 48h Stimulation 
It was then hypothesised that the length of stimulation was insufficient to elicit a 
significant GLUT1 response from the cells. PBMC were therefore stimulated with 
PMA/ionomycin (25 ng/mL and 0.5 µg/mL, respectively) for 48 h. There was a 
distinguishable positive population compared to the unstimulated treatment group 




Figure 10. GLUT1 titration 
Human PBMC were either A: Unstimulated, or B: stimulated with PMA/ionomycin (25 ng/mL and 
0.5 µg/mL, respectively) for 48 h. After which, PBMC were stained with an AF594 fluorophore 
conjugated antibody against the GLUT1 transporter. PBMC were stained with increasing concentration of 
the antibody in the same staining volume. Fluorescence minus one (FMO) does not contain any antibody 
against GLUT1. All treatments also contain antibodies against CD3 and CD19 to allow for T cell specific 
gating. Data measured by spectral flow cytometry and analysed using FlowJo™v10. Red box indicates 
the selected concentration of antibody. 
The stain index is a quantification of the separation between the negative and positive 
populations, and was used to aid in deciding upon the most appropriate concentration of 
antibody. To calculate the staining index, gates were drawn around the positive and 
negative GLUT1 populations for all antibody concentrations using FlowJo™v10. The 
median fluorescence intensity (MFI) of the GLUT1- population was subtracted from the 
MFI of the GLUT1+ population. The resulting number was then divided by 2x the 
standard deviation of the GLUT1- population (Table 6). The staining index is 
represented in graphical format in Figure 11. 
Table 6. GLUT1 staining index 
 
Concentration (µg/mL) GLUT1+ Median GLUT1- Median GLUT1- SD Staining Index
0.67 5006 302 374 6.3
1 5865 281 362 7.7
2.5 13649 295 422 15.8
5 25336 389 908 13.7
10 40391 425 2054 9.7
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The highest staining index of 13.7 for stimulated cells was the 2.5 µg/mL concentration 
(Figure 11). Visually, this group had a tight positive population and minimal spread of 
the negative population compared to the other antibody concentrations and was thus 
selected as the concentration of GLUT1 antibody moving forward. 
 
Figure 11. Staining index for GLUT1 titration 
Human PBMC were stimulated with PMA/ionomycin (25 ng/mL and 0.5 µg/mL, respectively) for 48 h 
and then stained with an AF594 fluorophore conjugated antibody against the GLUT1 transporter. PBMC 
were stained with increasing concentration of antibody in the same staining volume. T cells were gated on 
specifically. Data was measured by spectral flow cytometry and analysed using FlowJo™v10 and 
GraphPad Prism v8. Staining index is calculated based on numerical values from Table 6. 
4.3 Determining Appropriate Controls for Spectral Unmixing 
PBMC and BD™ CompBeads were stained using the same concentration of each 
fluorophore in the panel. The MFI of the spectral patterns for each fluorophore was 
exported from SpectroFlo® to a Microsoft Excel™ spreadsheet, where they were 
normalised. For all antibodies except CD26 (also known as dipeptidyl peptidase [DPP4] 
but herein referred to as CD26) and GLUT1, the spectral signatures were visually 
similar enough to use BD™ CompBeads as controls (Appendix 3, Figure S3). 
CompBeads cannot be stained by a tetramer because tetramers do not have an Fc region. 
To circumvent this, an antibody against CD27 (clone M-T271, BD Horizon) which was 















conjugated to the same fluorophore as the MR1 tetramer, BV421, was used at a dilution 
of 1:200 to stain CompBeads, as the spectral signatures should theoretically be the 
same. 
4.4 Assessing Fluorophore Spread for Compensation 
The experiment containing the core panel of antibodies was unmixed using beads for all 
fluorophores based on results from the previous section. Although cells stained with the 
CD26 and GLUT1 antibodies gave different normalised signatures to the stained 
CompBeads, CompBeads was used as the control for these antibodies because, as 
assessed by the NxN plots, populations looked cleaner when CompBeads were used as 
opposed to cells (Appendix 3, Figure S4). NxN plots for all fluorophores were visually 
assessed. Stimulated cells were focussed on as these were more likely to express 
cytokines, however unstimulated cells were also assessed to ensure that any changes 
caused as a result of stimulation were taken into account. When the fluorophore 
conjugated to the MR1 tetramer, BV421 was unmixed using beads as the control, it was 
clear that there was an issue with this antibody as the MR1 positive population was 
veering towards the left of the plot as opposed to being perpendicular with the IFNγ 
positive population. This was visually more obvious in the unstimulated cells (Figure 
12A). When the MR1 tetramer was unmixed using cells instead of beads, the issue 
seemed to resolve (Figure 12B). The NxN plots for all 16 fluorophores on stimulated 
cells is shown in Appendix 3, Figure S5. 
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Figure 12. Unstimulated MR1 NxN 
Unstimulated Human PBMC were stained using a core panel of 12 markers. Y-axis is showing 5-OP-RU 
loaded MR1 tetramer conjugated to BV421 fluorophore. X-axis is all antibody-conjugated fluorophores in 
the core panel. A: has been unmixed using BD™ CompBeads as a control for MR1. Red circle indicates 
the area where compensation issues were occurring. B: has been unmixed using cells as a control for 
MR1. Red circle indicates the same area where the compensation issue has been fixed. 
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4.5 Assessing Staining Resolution and Negative Population Spread 
Cell stained singularly with each fluorophore were compared to cells stained with the 
full antibody panel. Graphs for all fluorophores in the panel were generated using 
FlowJo™v10 and assessed visually. Fluorophores analysed had a clear positive 
population and similar staining profiles, with minimal spread of the negative 
populations, indicating that the full antibody mix was not interfering with the individual 
staining if any of the fluorophores (Appendix 3, Figure S6). There was one exception. 
BUV496 which marks for CD26 did not have distinguishable negative and positive 
populations. CD26 was however still included in the final panel because the staining 
recapitulated staining results from other researchers, discussed in the discussion section. 
4.6 Run of Optimised 16 Colour Panel 
The panel was optimised according to the aforementioned panel optimisation steps and 
contained 16 markers in total (Table 1). Stimulated populations were generally focussed 
on as they are more likely to express cytokines. Gating strategy outlined in Figure 8 was 
followed for all analyses. Any further gating was conducted as outlined in the 
appropriate section. 
4.6.1 PLZF is Important For IFNg  Production 
ILT cell subsets were identified using their lineage markers. CitSyn and PLZF were 
plotted against each other and gates were drawn around the CitSyn+, PLZF+ and 
CitSyn+, PLZF- populations. IFNg production was measured as the percentage of cells 
positive for IFNg of the parent population. A gate was thus drawn around the IFNg+ 
population within these groups, using an IFNg FMO to guide where to place the gates 
for each cell type (Figure 13). 
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Figure 13. Gating strategy used to assess of PLZF effect on IFNg expression 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. Gating strategy outlined in Figure 8 was 
followed to identify T cells using FlowJo™v10. Each innate-like T cell subset was subsequently 
identified based on their lineage markers. Pictured are MAIT cells (CD3+ and MR1-tetramer+ from one 
participant) A: Citrate synthase (CitSyn) was plotted against PLZF. All cells were CitSyn+. Gates were 
drawn around PLZF+ and PLZF- populations. B: The PLZF+ population was selected, and IFNg was 
plotted to determine percentage of cells expressing IFNg. C: The PLZF- population was selected, and 
IFNg was plotted to determine percentage of cells expressing IFNg. D: The IFNg FMO which was used to 
determine where to set the gate for the PLZF+ population. E: The IFNg FMO which was used to 
determine where to set the gate for the PLZF- population. Cells used to generate FMOs were pooled from 




























Data was analysed by two-way ANOVA with cell type and PLZF as the two factors. 
There was no significant effect of cell type, but there was a significant effect of PLZF 
(P < 0.0001). The interaction between both factors was not significant. A post-hoc 
Sidak’s multiple comparisons test confirmed a significant difference in all three ILT 
subsets based on the presence or absence of PLZF (Figure 14). This data demonstrates 
the importance of PLZF for optimal IFNg production.  
 
Figure 14. Effect of PLZF on ILT cell IFNg expression 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. Data was analysed using FlowJo™v10 and 
GraphPad Prism (v8). Analysis was performed on one replicate of N = 10 participants. A two-way 
ANOVA was performed with “cell type” and “PLZF” as the two factors. There was no significant effect 
of “cell type”, but there was a significant effect of “PLZF” (P <0.0001). The interaction between both 
factors was not significant. A post-hoc Sidak’s multiple comparisons test was performed to assess effect 
of “PLZF” on percentage positive “IFNg”. iNKT cells (P = 0.0001), MAIT and Vg9+Vd2+ T cells 
(P <0.0001). Error bars are standard error of the mean. 
4.6.2 PLZF may be Important for IL-4 Production in iNKT Cells 
As iNKT cells are the typical ILT cell IL-4 producers,154 IL-4 production was 
investigated in these cells. iNKT cells were identified out of CD3+ T cells based on 
binding of an antibody to TCR Va24-Ja18. Specific gating strategy was followed as is 
outlined in Figure 13, but with IL-4 in place of IFNg. We observed higher IL-4 
production in PLZF+ iNKT cells overall, however this difference was not statistically 


















Figure 15. Effect of PLZF on iNKT cell IL-4 production 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. iNKT cell populations were identified based 
on binding of TCR Va24-Ja18 (clone 6B11) antibody conjugated to the PE fluorophore. Data was 
analysed using FlowJo™v10 and GraphPad Prism (v8). Paired t-test was performed on one replicate of N 
= 10 participants. Data is not statistically significant. 
4.6.3 Differences in Citrate Synthase Production Does Not Affect Cytokine Expression 
When ILT Cells are Not Expressing PLZF 
Although all cells were CitSyn+, we noticed distinct high and low CitSyn populations in 
cells lacking PLZF (Figure 16). Cytokine expression was therefore analysed in cells that 
were PLZF- and CitSynhigh, and compared to cells that were PLZF- and CitSynlow to 
investigate whether metabolic state has an effect which might have been masked by the 













Figure 16. Distinct PLZF-, citrate synthase high and low populations 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. Distinct populations expressing high and 
low citrate synthase (CitSyn) that were PLZF- prompted further investigation about the potential different 
metabolic output of these populations. Image is of an iNKT cell population (CD3+ and Va24-Ja18+) from 
one participant. Data was analysed using FlowJo™v10. 
The percentage of cells positive for each cytokine in the panel – IL-4, IL-17 and IFNg - 
was calculated for both the CitSynhigh and CitSynlow populations. A two-way ANOVA 
was performed with CitSyn and cell type as the two factors. There was no significant 
difference in cytokine expression for any of the cytokines investigated (Figure 17). 
MAIT cell IL-17 expression was significantly higher than iNKT and Vg9+Vd2+ T cell 
groups in both the CitSynlow and CitSynhigh populations, indicating that MAIT cells 
generate more IL-17 than the other ILT cell subsets (Figure 17C). 
These results suggest that PLZF has a dominant impact on cytokine secretion in ILT 
cells, and that differences in TCA cycle activity within PLZF- ILT cell subsets do not 












Figure 17. Cytokine expression of high and low expressing citrate synthase populations in 
PLZF- innate-like T cells 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. Analysis was performed on the percentage 
of cells positive for the selected cytokine on one replicate of N = 10 participants. A two-way ANOVA 
was performed with “cell type” and “CitSyn” as the two factors. The interaction between both factors was 
not significant for any of the cytokines analysed. A: There was no significant effect of “CitSyn” 
on %IFNg(+), however there was a significant effect of “cell type” (P = 0.003). B: There was no 
significant effect of “CitSyn” or “cell type” on %IL-4(+). C: There was no significant effect of “CitSyn” 
on %IL-17(+), however there was a significant effect of “cell type” (P < 0.0001). Error bars are standard 
error of the mean. Data was analysed using FlowJo™v10 and GraphPad Prism (v8). 
4.6.4 Differential Requirement of CitSyn for Cytokine Secretion in CD4+ and CD8+ T 
Cells  
Since differential expression of CitSyn did not lead to significant differences in 
cytokine secretion in PLZF- ILT cells (see previous section), I next evaluated the effect 
of CitSyn on conventional T cells, which lack PLZF by nature. Conventional T cells 









































the negative populations for all of the ILT cell markers, before finally identifying CD4+ 
Th and CD8+ Tcyt cell populations. 
In PBMC-derived conventional T cells, the level of IFNg and IL-17 production was 
influenced by CitSyn level (high/low) and cell type. CD8+ Tcyt cells had higher baseline 
IFNg levels (P = 0.022), and CD4+ Th cells had higher baseline IL-17 levels (P = 0.024). 
Within a particular cell type, whether CitSyn was high or low had an impact on IFNg 
production. This was supported by a two-way ANOVA analysis in which there was a 
significant interaction between the two factors for both IFNg and IL-17 (Figure 18A and 
C). A post-hoc Sidak’s multiple comparisons test was performed to assess CitSyn on 
IFNg production. The significance in CD8+ Tcyt cells was P = 0.0004 (Figure 18A). The 
same post-hoc test was used to assess the effect of CitSyn IL-17 production, with the 
significance in CD4+ Th cells of P = 0.002 (Figure 18C). We observed higher IL-4 
production in CitSynhigh populations in both cell types, however the interaction between 
CitSyn and cell type on IL-4 production was not statistically significant (Figure 18B). 
Thus, high CitSyn expression was associated with higher IFNg production in CD8+ Tcyt 





Figure 18. Cytokine expression of high and low expressing citrate synthase populations in 
PLZF- conventional T cells 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. Analysis was performed on the percentage 
of cells positive for the selected cytokine on one replicate of N = 10 participants. A two-way ANOVA 
was performed with “cell type” and “CitSyn” as the two factors. A: The influence of “CitSyn” and “cell 
type” on %IFNg(+) was substantiated by a two-way ANOVA that indicated an interaction between the 
two factors (P = 0.022). A post-hoc Sidak’s multiple comparisons test was performed to assess “CitSyn” 
on %IFNg(+). CD8+ Tcyt (P = 0.0004). B: There was no significant effect of “CitSyn” or “cell type” 
on %IL-4(+). C: The influence of “CitSyn” and “cell type” on %IL-17(+) was substantiated by a two-way 
ANOVA that indicated an interaction (P = 0.024). A post-hoc Sidak’s multiple comparisons test was 
performed to assess “CitSyn” on %IL-17(+). CD4+ Th (P = 0.002). Error bars are standard error of the 
mean. Data was analysed using FlowJo™v10 and GraphPad Prism (v8). 
These results differ from the finding in ILT cell subsets, where there was no interaction 
between CitSyn level and cell type for any of the cytokines in the analysis. 
4.6.5 High Citrate Synthase Expression is Correlated with High GLUT1 Expression in 
Stimulated ILT Cells 
As CitSyn is a metabolic enzyme associated with the TCA cycle, increased expression 












































a relatively new way to assess metabolism, and more investigation is needed to verify 
the specifics of this relationship. We therefore next investigated CitSyn in relation to the 
other metabolic marker, GLUT1. The gMFI of GLUT1 was recorded for populations of 
cells that were CitSynhigh and CitSynlow regardless of PLZF expression. Since PLZF 
expression had such a dominant impact on cytokine secretion in ILT cells, we did not 
seek to correlate GLUT1 expression with cytokine production, but rather exclusively 
looked that the relationship between CitSyn and GLUT1. gMFI was used as the 
quantitative measure because it is a measure of how much GLUT1 is physically being 
produced within the population, as opposed to the number of cells producing it, 
therefore it would identify if there was a high quantity of GLUT1 being expressed by a 
small number of cells. High CitSyn expression was associated with high GLUT1 
expression in all three stimulated ILT cell subsets investigated (Figure 19B), confirming 
an increased metabolic state. In unstimulated cells, there was no significant increase in 
GLUT1 expression on iNKT or Vg9+Vd2+ T cells when CitSyn expression was high, 
but there was a significant increase in MAIT cells (Figure 19A). 
These results indicate that CitSynhigh cells are not only metabolically distinct at steady 
state but are also characterized by a readiness to upregulate other metabolic features 
upon activation. They also indicate a relationship between CitSyn and GLUT1, as when 
stimulated, CitSynhigh is associated with increased GLUT1, demonstrating their 




Figure 19. Citrate synthase expression relationship with GLUT1 
PBMC were either stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), or 
unstimulated. Cells were stained using a 16 colour panel and measured using spectral flow cytometry. 
Analysis was performed on the geometric mean fluorescence intensity (gMFI) on one replicate of N = 10 
participants. Paired t-tests were performed on each of the ILT cell subsets individually to assess whether 
being CitSynhigh was associated with an increase in GLUT1 expression. A: Unstimulated cells. MAIT (P 
< 0.0001). B: Stimulated cells. iNKT (P = 0.009), MAIT (P < 0.0001), Vg9+Vd2+ (P < 0.0001). Error bars 
are standard error of the mean. Data was analysed using FlowJo™v10 and GraphPad Prism (v8). 
4.6.6 CD26 is Correlated with IFNg Expression in iNKT and MAIT Cells 
Since PLZF seems to have a great impact on ILT cytokine secretion, we looked for 
other markers which characterize this population and thus plotted PLZF against CD26 

































Figure 20. MAIT cell PLZF and CD26 expression profiles 
Unstimulated PBMC were stained using a 16 colour panel and measured using spectral flow cytometry. 
Pictured are MAIT cells (CD3+ and MR1-tet+) from one participant. CD26 and PLZF are plotted to 
visualise the relationship between these markers. 
The frequency of ILT cells that were PLZF and CD26 double positive and double 
negative was calculated for each participant in both unstimulated (Figure 21) and 
stimulated groups. We observed that the majority of PLZF+ MAIT cells were also 
CD26+. A similar pattern was observed in iNKT, but not Vg9+Vd2+ T cells. Stimulation 




Figure 21. Percentage of ILT cells expressing PLZF and CD26 
Unstimulated PBMC were stained using a 16 colour panel and measured using spectral flow cytometry. 
Analysis was performed on one replicate of N = 10 participants. Graph illustrates the percentage of the 
various ILT cell subsets that were either double positive for PLZF and CD26, or double negative. Data 
was analysed using FlowJo™v10 and GraphPad Prism (v8). 
4.6.7 CD26 is Important for IFNg Expression in iNKT and MAIT Cells 
To confirm the close association between PLZF and CD26, cytokine secretion of CD26+ 
ILT was compared to CD26- as it was for PLZF in section 4.6.1. The effect of CD26 on 
cytokine expression was similar to the effect of PLZF in both iNKT and MAIT cells. 
Interestingly the opposite was observed in Vg9+Vd2+ T cells. i.e. CD26- iNKT and 
MAIT cells express less IFNg than Vg9+Vd2+ T cells (Figure 22). Within a particular 
cell type, whether CD26 is expressed impacts IFNg expression. This is supported by the 
two-way ANOVA analysis in which there is a significant interaction between the two 
factors (P < 0.0001) (Figure 22). Thus, there is a close relationship between PLZF and 
CD26 in all ILT subsets, but Vg9+Vd2+ T cells appear to behave differently to iNKT 





















Figure 22. Effect of CD26 on ILT cell IFNg expression 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. Analysis was performed on one replicate of 
N = 10 participants. A two-way ANOVA was performed with “cell type” and “CD26” as the two factors. 
The interaction between factors was significant (P < 0.0001). A post-hoc Sidak’s multiple comparisons 
test was performed to assess effect of “CD26” on percentage positive “IFNg”. All P values < 0.0001. 
Error bars are standard error of the mean. Data was analysed using FlowJo™v10 and GraphPad Prism 
(v8). 
4.6.8 CD26 is Important for IL-4 Expression in iNKT Cells 
iNKT cells are the typical ILT cell IL-4 producers. As such, IL-4 production was 
investigated in the context of CD26 in these cells, as it was for PLZF in section 4.6.2. 
CD26+ iNKT cells expressed significantly more IL-4 compared to those not expressing 
CD26 (P = 0.0196) (Figure 23), further confirming the role of CD26 in cytokine 


















Figure 23. Effect of CD26 on iNKT cell IL-4 production 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. iNKT cell populations were identified based 
on binding of TCR Va24-Ja18 (clone 6B11) antibody conjugated to the phycoerythrin (PE) fluorophore. 
Data was analysed using FlowJo™v10 and GraphPad Prism (v8). Paired t-test was performed on one 
replicate of N = 10 participants (P = 0.0196). 
4.6.9 CD26 Presence Inhibits Cytokine Expression in CD8+ Tcyt Cells 
The relationship between CD26 and cytokine expression was then investigated in 
conventional T cells, specifically CD8+ Tcyt cells, to assess for differences in behaviour 
across cell groups. CD4+ Th cells were not investigated in this context due to errors with 
the FMO. Interestingly, in CD8+ Tcyt cells the opposite relationship to ILT cells was 
found, with higher cytokine expression observed in cells not expressing CD26 (Figure 
24). This data demonstrates the difference in functional requirements between 














Figure 24. CD26 on cytokine expression in conventional CD8+ Tcyt cells 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. Analysis was performed on one replicate of 
N = 10 participants. Paired t-tests were used to analyse IFNg and IL-17 in relation to CD26 expression in 
stimulated CD8+ cytotoxic T cells A: Percentage of CD8+ cells expressing IFNg (P = 0.0003). B: 
Percentage of CD8+ cells expressing IL-17 (P = 0.0084). Data was analysed using FlowJo™v10 and 





























5.1 Key Findings 
The study has established a methodology for in vitro study of PBMC-derived innate-
like and conventional T cells based on the Met-Flow technique. Using a cohort of 
metabolically healthy participants, confirmed by HbA1c analysis, we successfully 
isolated PBMC from whole blood and developed and optimised a spectral flow 
cytometry panel which enabled phenotype recognition of specific T cell subtypes and a 
range of metabolites, transporters and cytokines to establish the foundation of a 
metabolic profile for ILT cells. We found that the transcription factor, PLZF plays a key 
role in the effector function of ILT cells, importantly that an increased metabolic state, 
measured by increased CitSyn expression, does not correlate to increased cytokine 
production when ILT cells are not expressing PLZF. We also highlight a relationship 
between PLZF and CD26 in ILT cells, as iNKT and MAIT cells appear to rely on both 
for optimal cytokine secretion, while Vg9+Vd2+ T cells are a more distinct subset as 
they have a more complicated relationship between these metabolites, which warrants 
further investigation. Finally, we found that conventional CD8+ Tcyt cells appear to have 
an inverse relationship with CD26 as compared to ILT, although we are limited in our 
ability to draw a conclusion on the frequency and function of these cells in AT at this 
stage. 
5.2 Participant Cohort 
Participants were recruited into this study if they were adults, aged > 18 years, had a 
self-identified BMI between 18 kg/m2 and 35 kg/m2, and were self-professed healthy 
i.e. had no known metabolic disease. No limitations were set on factors such as ethnicity 
or age over and above being a legal adult in New Zealand. This was to ensure as many 
participants as possible were recruited for this pilot study. Age and ethnicity were not 
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stratified into groups because we were operating under the assumption that there should 
be no major differences at the cellular level between groups, and because the sample 
size was too small to be powered to make claims based on these factors. 
5.3 HbA1c Analysis 
HbA1c is a measure of the amount of haemoglobin bound to glucose. As red blood cells 
only survive in humans for a few months, HbA1c gives an indication of the average 
amount of glucose in the blood over this period of time. Individuals are considered high 
risk for developing T2DM if they have an HbA1c concentration above 40 mmol/mol, 
and having T2DM when HbA1c is above 50 mmol/mol.155 HbA1c testing was 
conducted in this study as an indicator of metabolic health. All participants in the study 
were in the normal range for HbA1c and are therefore considered metabolically healthy. 
Because HbA1c concentration is inversely correlated with MAIT cell numbers in 
peripheral blood,116 it would have been interesting to correlate MAIT and the other ILT 
cell numbers with HbA1c. However because we only studied healthy individuals with 
an HbA1c < 40 mmol/mol we were unable to compare the cells populations across a 
range of glycaemic states. 
5.4 Titration of GLUT1 and Citrate Synthase Antibodies 
GLUT1 and CitSyn were titrated using a 48 h and a 1 h stimulation respectively, using 
PMA and ionomycin at either 25 ng/mL and 0.5 µg/mL, or 50 ng/mL and 1 µg/mL, 
respectively. The run of the optimised 16 colour panel was analysed after a 6 h 
stimulation in PMA/ionomycin at concentration of 50 ng/mL and 1 µg/mL, respectively. 
A 6 h stimulation was chosen for the final run because it allows for the best cytokine 
production and therefore visualisation. These differing stimulation time points and 
concentrations between the titration and the final run is not the recommended way of 
optimising a panel. As is outlined in the results section, differences in GLUT1 
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expression were indetectable following a 1 h stimulation, but it was detectable after a 48 
h stimulation. It is known that activated T cells increase GLUT1 expression as they 
undergo aerobic glycolysis.85 However, GLUT1 antibodies are notoriously difficult to 
work with in flow cytometry as they react poorly with the extracellular domain of the 
GLUT1 protein, and murine models are often myelocytomatosis (MYC)-tagged156 
which is not feasible for human work. Post-translational modification of GLUT1 
protein, for example glycosylation, could also affect the antibody’s ability to bind.157 
Given more time, other methods of increasing staining for GLUT1, such as sequential 
staining, or increasing temperature of staining conditions,158 would have been tested. 
Sequential staining can be beneficial when there are many antibodies in a panel as it 
allows time for the antibody to bind to its target without competition from the other 
antibodies. 
Although there was no significant GLUT1 binding when it was used as a cell surface 
marker, the intracellular GLUT1 was visible as a smear from the negative, with a higher 
fluorescence intensity overall compared to cell surface stained GLUT1, even in 
unstimulated cells (Appendix 3, Figure S1 and S2). This indicates that, although 
unstimulated cells may have very little active GLUT1, there appears to be a substantial 
amount of pre-formed GLUT1 in the cytosol, ready for an activation signal. Although 
some intracellular staining could be GLUT1 found on the mitochondrial membrane,159 it 
is unlikely that this is the sole source. 
5.5 PLZF is Important for Cytokine Expression in ILT Cells 
The dataset that this panel has generated is of considerable size and was therefore not 
able to be analysed on every single parameter in the given timeframe. The relationship 
between PLZF, and cytokine expression was analysed as it is a relatively under-
researched area of immunometabolism. All three ILT cell subsets had increased IFNg 
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expression when also expressing PLZF, indicating PLZF as a factor influencing IFNg 
production in these cells. In the AT of obese individuals, iNKT cells downregulate 
PLZF and upregulate another transcription factor, E4BP4 to influences their IL-2 and 
IL-10 expression,122 thus it would seem that AT can have a deep impact on PLZF 
expression, making it necessary to understand how changes in the expression of this 
master transcription factor alter the metabolic activity of ILT cells. As, due to COVID-
19, the data in this thesis was only obtained in peripheral blood-derived cells, results are 
not directly comparable to AT, but building on this by looking at MAIT and Vg9+Vd2+ 
as well as iNKT would be a point of interest when investigating AT-derived cells in the 
future. Importantly, IL-4 production seemed to be trending towards an increase in iNKT 
cells expressing PLZF. Further research is required to determine the relevance and 
potential significance of this. 
5.6 Innate-like and Conventional T Cells Lacking PLZF Differ in Cytokine 
Expression in the Context of Citrate Synthase 
The majority of work so far for ILT cells has been conducted in PLZF+ populations due 
to the abundance of literature describing its importance in ILT development and effector 
function.132, 133, 160 PLZF- ILT populations are only gradually becoming understood as 
novel research uncovers their specific functionality,122 therefore, ILT cells lacking 
PLZF were analysed in terms of their cytokine output. CitSyn expression was used as a 
metabolic marker with the assumption that increased CitSyn expression corresponded to 
an increased metabolic state. This assumption was based on CitSyn being a key enzyme 
in the TCA cycle. There was no significant difference in cytokine expression across 
populations of PLZF- ILT cells expressing high or low CitSyn i.e. cytokine expression 
is independent of CitSyn expression in all PLZF- ILT cell subsets. This data 
compliments previous work establishing PLZF as a key cytokine regulator in these 
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cells.161 But the question remains regarding the function of PLZF- ILT cells, and will 
continue to be addressed as the panel grows and moves into AT. 
Conversely, cytokine production in conventional T cells which are by nature PLZF-, 
seems to be somewhat related to increased CitSyn production, although it is important 
to note that not all ILT cell subsets were able to be removed and therefore some minor 
subsets may remain in the analysis. Higher IFNg production was seen in CD8+ Tcyt cells 
that were expressing higher levels of CitSyn, and so were CD4+ Th cells, which 
produced more IL-17. These results require further investigation, particularly because 
the two groups of conventional T cells have not been sub-categorised by status to 
discriminate between naïve and various effector and memory T cell subsets, or Treg 
cells, which have been shown to have different metabolic reliance.83 
5.7 High Citrate Synthase Expression is Correlated with High GLUT1 
Expression when ILT Cells are Stimulated 
Unstimulated iNKT and Vg9+Vd2+ cells, but not MAIT cells, seem to express similar 
levels of GLUT1 regardless of CitSyn expression, which could explain why binding of 
GLUT1 on unstimulated cells was so minimal in the titration phase of this project. The 
association in MAIT cells remains upon stimulation, and the other two subsets appear to 
acquire the association after stimulation. As discussed previously, GLUT1 was found in 
a much higher concentration when stained for intracellularly compared to the cell 
surface after a 1 h stimulation; and after 48 h of stimulation, some of this translocated to 
the membrane. Studies visualising GLUT1 for flow cytometry generally use protocols 
with a stimulations between overnight and 48 h.162, 163 It is possible that detectable 
levels of GLUT1 are expressed only when stimulation has occurred to allow an influx 
of glucose into the cell as a metabolic fuel. Stimulations between 1 and 6 h may have 
therefore been insufficient to promote GLUT1 translocation to the cell membrane, 
which could explain the similarity between the stimulated and unstimulated groups in 
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the initial titration for this antibody. In the original Met-Flow paper, Ahl et al found 
lower expression of GLUT1 on T cells and NK cells compared to other immune cell 
subsets, but a three-fold increase in T cell GLUT1 after a 24 h stimulation using 
Gibco™ Dynabeads Human T-Activator CD3/CD28, however CitSyn was not included 
in their panel of metabolic markers.83 Further investigation is required to fully 
understand the driving force behind the differences in the use of GLUT1 and CitSyn 
within ILT cells. 
5.8 CD26 Appears to Play a Role in ILT Cytokine Expression 
Consistent with a very recent report, the majority of human PLZF+ MAIT cells were 
also CD26+.164 The relationship between PLZF and CD26 has not been investigated 
fully in ILT cells. It is interesting that Vg9+Vd2+ cells do not seem to associate CD26 
with PLZF, as majority of Vg9+Vd2+ cells were not either double positive or double 
negative. Furthermore, CD26 presence is associated with IL-4 expression in iNKT cells, 
and IFNg expression in iNKT and MAIT cells, but its absence is associated with an 
IFNg response in Vg9+Vd2+ cells. A recent study found highly variable CD26 
expression in Vd2+ T cells, with CD26high, CD94high Vd2+ cells exhibiting MAIT-like 
characteristics.164 These data demonstrate the need to continue analysing ILT subsets in 
relation to one another to determine their specific metabolic profiles. 
Variable levels of CD26 expression is found on different subsets of Th cells,165 and it 
has been described as negative marker for Treg cells.166 A study investigating the effect 
of co-stimulation on CD8+ T cells i.e. CD3 plus either CD26 or CD28, found that CD26 
co-stimulation increased CD8+ T cells’ cytotoxic effect, measured by increased IFNg, 
granzyme-B and TNF-α.167 This is in contrast to our finding that CD26- Tcyt cells 
express more IFNg than CD26+ cells, although the study uses sorted CD8+ cells and thus 
could include ILT subsets in the analysis. 
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CD26 inhibitors, commonly known as gliptins, are currently being used to treat diabetes 
due to their ability to degrade the incretin, GLP-1, indicating the role of CD26 in 
glucose tolerance.168-170 It is possible that some of the therapeutic benefit of CD26 
antagonists may be mediated by blocking cytokine secretion in CD26+ ILT cells. There 
is some evidence to suggest that T cell-derived IFNg may contribute to the metabolic 
abnormalities seen in human obesity,171 so reducing this inflammatory cytokine could 
reduce the inflammatory AT environment characterising obesity. Additionally, CD26 
blocking has been used to improve lung allograft acceptance by reducing T cell IL-17 
production.172 Because results presented in this thesis reflect an opposite effect of CD26 
on cytokine production in CD8+ conventional T cells, further investigation is required in 
this area before any conclusive remarks can be made regarding the effect of CD26 
inhibition on specific T cell subsets. 
5.9 Strengths and Limitations 
The Met-Flow methodology enables single-cell resolution of key metabolic proteins in 
distinct immune cell populations of a heterogeneous sample, and is therefore a valuable 
novel tool for the field of immunometabolism. The ability to characterise immune cells 
on a single cell basis by their metabolic profiles provides a new lens on 
immunometabolic research, allowing a deeper understanding of homeostatic and 
dysfunctional settings. Novel therapeutic targets could be uncovered using the Met-
Flow technique which may not have otherwise been considered, both in the context of 
metabolic disease, and human disease in general. 
One of the inherent strengths of the Met-Flow methodology is the ability to measure the 
metabolic state of immune cells by targeting functional proteins on a single-cell level 
instead of mRNA, which are susceptible to post-transcriptional modification.85, 173 
Using 10 metabolic proteins, Ahl et al demonstrated the ability to identify and 
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characterise metabolically distinct immune cell subtypes, confirming the populations 
using lineage markers also included in their panel. Targeting the 10 genes encoding 
these proteins using single cell RNA sequencing (scRNAseq) did not afford the same 
ability to resolve distinct populations.83 
The panel designed by Ahl et al included 27 colours, targeting a range of 
immunological cells including myeloid cells, dendritic cells, monocytes and leukocytes. 
Having a breadth of cellular targets enables a higher number of fluorophores to be 
included in a single panel because co-expression is reduced. The panel created in this 
thesis investigates only T cells, and therefore is limited in its capacity to generate a 
panel with a high number of co-expressed targets. Considering this, it is possible to 
continue adding colours if care is taken with regard to co-expression and fluorochrome 
similarity.144 An advantage that this panel has over the original Met-Flow panel is its 
ability to differentiate between ILT subsets. Ahl et al include both CD4 and CD8 in 
their panel, but differences in ILT cells also expressing these molecules174, 175 means 
that individual differences in metabolic programming between subsets could be masked 
by conclusions pertaining to a holistic view of CD4+ and CD8+ T cells. 
It might be worthwhile to address the immunometabolism of ILT cells from multiple 
angles in addition to the Met-Flow technique. Extracellular flux has been demonstrated 
as a valuable tool to measure glycolytic activity and mitochondrial respiration by 
measuring the extracellular acidification (ECAR) and oxygen consumption rate 
(OCAR).53 Comparing data obtained in this way to spectral flow cytometric analysis 
could provide a more well-rounded insight into ILT metabolism. However, a primary 
limitation of these methods of investigation is they they fail to provide spatial 
information, which will become more relevant when the panel is being used on AT. The 
stromal vascular fraction will be isolated, and cells will be washed and stained using the 
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panel, however this will bring cells not usually near each other in vivo together and thus 
the spatiotemporal aspect of the cells functionality is not considered. 
Panel design and optimisation is a time-consuming process involving many steps. Not 
all research is designed to be this slow-moving. The generation of a working panel for 
PBMC-derived ILT cells which is theoretically able to be transferred to any tissue with 
the correct optimisation techniques applied is valuable to the field of 
immunometabolism, and additional markers could theoretically be added to look at 
pathogenesis of diseases not related to obesity-induced metabolic disease. As ILT cells 
are just beginning to be analysed in humans as opposed to the more conventional 
murine model, this project begins the transfer of knowledge from mice over to humans. 
Due to the lack of AT availability, all research was conducted on human PBMC, and 
although it is valuable to see trends and cause-and-effect relationships in these cells, 
there is no physiological relevance in the context of obesity and related pathologies until 
the panel has been optimised and run on immune cells isolated from AT, or if 
participants with varying levels of metabolic disease are recruited. Additionally, the 
panel must be grown to incorporate lineage markers for other subsets of T cells, 
including naïve and central and effector memory subsets, and additional metabolic 
markers for a more comprehensive understanding of the relationship between metabolic 
inputs and outputs within immune cells.  
5.9.1 Suitability of in vitro Stimulation Method 
In a study by Fu et al, stimulation by CD3/CD28 of iNKT cells induced aerobic 
glycolysis and a positive feedback loop involving TCR recycling that upregulated IFNg 
production.84 This process was not observed when iNKT cells were stimulated with 
PMA/ionomycin, indicating that TCR engagement is necessary for optimal effector 
function. Therefore, for more biological relevance, experiments simulating iNKT cells 
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should involve a TCR-specific activator, such as α-GalCer. Li et al individually 
stimulated ILT cell groups with their prototypical antigens, as well as PMA/ionomycin 
and, although cytokine secretion was similar for some groups, PMA/ionomycin seemed 
to elicit a higher response in others.130 Additionally, as mentioned previously, Ahl et al 
stimulated T cells using CD3/CD28 Dynabeads,83 which activate T cells via TCR 
engagement and co-stimulation,176 and is therefore more physiologically relevant 
compared to PMA/ionomycin. In order to better understand in vivo functionality of ILT 
cells, antigen-specific stimulation might be a more appropriate model. 
5.9.2 MR1 Tetramer Suitability 
The justification for using the 5-OP-RU loaded MR1 tetramer as opposed to identifying 
MAIT cell populations based on being CD161high, Vα7.2+ is due to MAIT cells’ ability 
to modulate their CD161 expression,93 together with Vα7.2 TCR not being entirely 
MAIT cell specific.177 Interestingly, MAIT cells also seem to drop their tetramer upon 
activation, a phenomenon observed by experiments in our lab. Although previous work 
describes the MR1 tetramer as the most accurate method of MAIT cell identification 
particularly in disease cohorts,95 it may be beneficial to include CD161 and Vα7.2 
antibodies as the panel grows to ensure all MAIT cells are detected. 
5.10 Future Directions 
The final panel contained 16 colours, or markers in total. The number of metabolic 
markers could be increased to gather information on T cell use of transcription factors, 
cytokines, metabolic enzymes, and binding proteins to build a more comprehensive 
metabolic profile for each subset. As stimulation using PMA/ionomycin is not 
physiologically relevant, an antigen specific stimulation model could be introduced for 
each ILT subtype, or alternatively, TCR specific simulation using CD3/CD28 
Dynabeads could be investigated. 
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The more immediate future direction for this project is to test the original hypothesis by 
acquiring AT samples from healthy participants and comparing ILT cell frequency and 
function to PBMC from the same participant. This will allow a more accurate picture of 
ILT cell metabolism and their influence in obesity and metabolic disease to be 
established. Furthermore, once a metabolic profile for ILT cells in healthy participants 
has been established, the project can begin to investigate metabolic reprogramming 
within participants with metabolic disease to assess for therapeutic targets. 
There are many possibilities when using the MetFlow technique. Immune cell 
metabolism could be investigated in a number of human ailments not limited to 
metabolic disease including allergy, vaccination, and gut health, as well as chimeric 
antigen receptor (CAR) T cell cancer therapy. Of course there are limitations in the 
transferability of a panel optimised on one tissue type to another, as each panel should 
be designed with the biology of the target tissue considered i.e. the autofluorescence of 
the tissue, well as the stability and the digestion protocol used to process it.144 
In the context of measuring single cell immunometabolism, the Met-Flow technique 
presented in this thesis is just one avenue allowing insight into the mechanics of 
immunology. A summary of the most relevant metabolic analyses and their inherent 
strengths and weaknesses is outlined by Artyomov and Van den Bossche.53 Specifically, 
Met-Flow measurements can only be made on metabolic intermediates and will 
therefore always be indirect. Incorporation of many applications, including Met-Flow, 
extracellular flux analysis, scRNAseq, mass cytometry, transcriptomics, proteomics and 
metabolomics will improve resolution on the single cell level. Additionally, developing 
techniques to achieve high quality subcellular resolution of metabolic intermediates 




There is a need for understanding the function of the immune system in the context of 
obesity and related pathologies in order to intervene with immunotherapies, and ILT 
cells represent a viable target due to their particular abundance in AT. 
The overall aim of this study was to increase understanding of the intrinsic metabolism 
of PBMC-derived ILT cells. Our data builds on previous work to characterise ILT cells 
in relation to one another and their conventional counterparts. In particular, that PLZF 
expression is associated with cytokine secretion in ILT cells. We also describe the close 
association between PLZF and CD26 in not only MAIT cells, but also iNKT cells, and 
have discovered that absence of PLZF in ILT cells suppresses immunometabolic 
pathways. Finally, we describe differences between ILT subsets, with iNKT and MAIT 
cells appearing to be more similar while Vg9+Vd2+ cells are more distinct. However, in 
the context of the original hypothesis of assessing the frequency and function of ILT 
cells in AT compared to peripheral blood, we are unable to draw a conclusion due to the 
unavailability of AT-derived cells. 
While a conclusion on the metabolism of AT-derived ILT cells and their similarity to 
peripheral blood-derived ILT cells cannot yet be determined, the foundations developed 
from this study provide a framework for research into ILT cell metabolism and has led 
to discoveries which I will develop further in my role as a Summer Research Intern at 
the Malaghan Institute of Medical Research. 
The highly topical nature of this work is reflected in the interest that has been shown so 
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 Ministry of Health 
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30 March 2020 
 
Miss Hannah van der Woude  





Dear Miss van der Woude  
 
Re: Ethics ref: 20/CEN/67 
 Study title: Analysis of innate like T cells in peripheral blood and adipose tissue of 
healthy men and women 
 
I am pleased to advise that this application has been approved by the Central Health and 
Disability Ethics Committee.  This decision was made through the HDEC-Expedited 
Review pathway. 
 
Conditions of HDEC approval 
 
HDEC approval for this study is subject to the following conditions being met prior to the 
commencement of the study in New Zealand.  It is your responsibility, and that of the 
d  ,  e e ha  he e c di i  are met.  No further review by the 




1. Before the study commences at any locality in New Zealand, all relevant 
regulatory approvals must be obtained. 
 
2. Before the study commences at each given locality in New Zealand, it must be 
authorised by that locality in Online Forms.  Locality authorisation confirms that 
the locality is suitable for the safe and effective conduct of the study, and that 




3. Please add the following to the Participant Information Sheet (PIS): 
a. In the section covering who has access to study data: include approved 
auditors from HDEC etc (see consent form). 
b. Exactly where the data will be stored. 
c.  In the section covering participant rights: add the right to see personal data 
collected and to make any corrections if necessary. 
d. The PIS a e  ha  Pa ici a  ca  ge  c ie  f e  a d e e a i  
if he  i h  b   a a  i  e i ed i  he c e  f . P ea e 
make this consistent and ensure this is a lay summary. 
 
Non-standard conditions must be completed before commencing your study, however, 
they do not need to be submitted to or reviewed by HDEC. 
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If you would like an acknowledgement of completion of your non-standard conditions you 
may submit a post approval form amendment through Online Forms. Please clearly 
identify in the amendment form that the changes relate to non-standard conditions and 
ensure that supporting documents (if requested) are tracked/highlighted with changes.  
 
For information on non-standard conditions please see section 128 and 129 of the 
Standard Operating Procedures for Health and Disability Ethics Committees (available on 
www.ethics.health.govt.nz) 
 
After HDEC review  
 
Please refer to the Standard Operating Procedures for Health and Disability Ethics 
Committees (available on www.ethics.health.govt.nz) for HDEC requirements relating to 
amendments and other post-approval processes.   
 
Your next progress report is due by 29 March 2021. 
 
Participant access to ACC 
 
The Central Health and Disability Ethics Committee is satisfied that your study is not a 
clinical trial that is to be conducted principally for the benefit of the manufacturer or 
distributor of the medicine or item being trialled.  Participants injured as a result of 
treatment received as part of your study may therefore be eligible for publicly-funded 
compensation through the Accident Compensation Corporation (ACC). 
 
Plea e d  he i a e  c ac  he HDEC ec e a ia  f  f he  i f a i .  We i h 





Mrs Helen Walker 
Chairperson 
Central Health and Disability Ethics Committee 
 
 
Encl: appendix A: documents submitted 




8.2 Appendix 2: Table of Antibodies for Flow Cytometric Analysis of Human PBMC 
Table S1. Comprehensive table of antibodies 
 
Antigen Fluorophore Clone Control Supplier Lot number Catalogue number Dilution Location Purpose 
Core Panel                   
- Zombie NIR - Cells BioLegend® B262815 77184 1:2000 Cell surface Viability 
CD3 BV510 UCHT1 Beads BioLegend® B281774 300448 1:100 Cell surface Pan T cell 
CD19 BB515 HIB19 Beads BD Horizon™ 9129583 564456 1:50 Cell surface Pan B cell 
Vα24-Jα18 PE 6B11 Beads BioLegend® B214138 342904 1:25 Cell surface iNKT cell 
MR1 tetramer BV421 - Cells NIH - - 1:800 Intracellular MAIT cell 
TCR Vg9 APC B3 Beads BioLegend® B206568 331310 1:200 Cell surface Vg9+ T cell 
TCR Vd2 PerCP-Cy5.5 B6 Beads BioLegend® B304597 331424 1:50 Cell surface Vd2+ T cell 
PLZF PE-CF594 R17-809 Beads BD Horizon™ 8099827 565738 1:200 Intracellular PLZF activity 
GLUT1 AF594 EPR3915 Beads Abcam GR3278748-2 ab206360 1:200 Cell surface Glucose transport 
IL-4 PECy7 MP4-25D2 Beads BioLegend® B211649 500824 1:300 Intracellular Immune regulation 
IL-17 BV711 BL168 Beads BioLegend® B234634 512328 1:50 Intracellular Inflammation 
IFNg eFluor450 4S.B3 Cells eBioscience 4295328 48-7319-42 1:200 Intracellular Inflammation 
Additions                   
Citrate Synthase AF647 EPR8067 Beads Abcam GR3281073-1 ab196860 1:100 Intracellular TCA activity 
CD4 BV605 OKT4 Beads BioLegend® B244137 317438 1:50 Cell surface CD4
+ T cell 
CD8 BUV395 RPA-T8 Beads BD Horizon™ 7069910 563795 1:100 Cell surface CD8
+ T cell 
CD26/DPP4 BUV496 M-A261 Beads BD Optibuild™ 197114 750667 1:200 Cell surface Immune regulation 
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8.3 Appendix 3: Panel Optimisation 
 
Figure S1. GLUT1 cell surface stain 
Human PBMC were either A: unstimulated or B: stimulated with PMA/ionomycin (50 ng/mL and 
1 µg/mL, respectively) for 1 h. After which, PBMC were stained on the cell surface with an Alexa Fluor 
594 fluorophore conjugated antibody against the GLUT1 transporter. PBMC were stained with increasing 
concentration of the antibody in the same staining volume of 50 µL. Fluorescence minus one (FMO) does 
not contain antibody against GLUT1. All treatments also contain cell surface-stained antibodies against 
CD3 – BV510 and CD19 – BB515 to allow for analysis on T cells specifically. Data measured by spectral 
flow cytometry and analysed using FlowJo™v10. 
 
Figure S2. GLUT1 intracellular stain 
Human PBMC were either A: unstimulated, or B: stimulated with PMA/ionomycin (25 ng/mL and 
0.5 µg/mL, respectively) for 48 h. After which, PBMC were stained intracellularly with an Alexa Fluor 
594 fluorophore conjugated antibody against the GLUT1 transporter. PBMC were stained with increasing 
concentration of the antibody in the same staining volume of 50 µL. Fluorescence minus one (FMO) does 
not contain antibody against GLUT1. All treatments also contain cell surface-stained antibodies against 
CD3 – BV510 and CD19 – BB515 to allow for analysis on T cells specifically. Data measured by spectral 





Figure S3. Spectrum overlay of single-stained cells and beads for each fluorophore 
Human PBMC and CompBeads were stained singularly with each fluorophore in the panel. Median 
fluorescence intensities were exported from SpectroFlo™ and normalised in Microsoft Excel. Beads and 
cells were overlayed. A: APC. B: BV510. C: BB515. D: BUV395. E: PECF594. F: PECy7. G: 
PerCPCy5.5. H: eFluor450. I: BV711. J: BV605. K: BV421. L: BUV496. M: PE. N: Alexa Fluor 594. 
O: Alexa Fluor 647. Zombie NIR™ must always be run on cells and therefore no cells vs. beads overlay 







Figure S4. CD26 NxN plots 
Human PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained 
using a 16 colour panel and measured using spectral flow cytometry. Y-axis is showing CD26 antibody 
conjugated to BUV496 fluorophore. X-axis is all antibody-conjugated fluorophores in the panel. A: has 
been unmixed using PBMC single stained using the CD26 antibody. B: has been unmixed using BD™ 
CompBeads single stained using the CD26 antibody. After visual assessment of the plots, CompBeads 
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Figure S5. NxN plots for each fluorophore in the final panel 
Human PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained 
using a 16 colour panel and measured using spectral flow cytometry. Gated on single cells à 
lymphocytes à live cells. (Figure 7A to D). A: Vα24-Jα18. B: CD3. C: CD4. D: CD8. E: CD19. F: 
CD26. G: Citrate synthase. H: GLUT1. I: IFNg. J: IL4 K: IL17 L: MR1. M: PLZF. N: TCR Vd2. O: 
TCR Vg9. P: Viability. Pictured are cells from one participant. 
  











Figure S6. Full stain comparison to single stain PBMC for each fluorophore 
Human PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), and 
stained with either the full antibody staining mix, or singularly with each fluorophore in the panel, and 
measured using spectral flow cytometry. Analysis was performed using FlowJo™v10. Gating strategy 
outlined in Figure 7 was followed. For single stains, viability could not be performed so cells were gated 
on cells of interest (lymphocytes)  A: APC. B: BV510. C: BB515. D: BUV395. E: PECF594. F: PECy7. 
G: PerCPCy5.5. H: eFluor450. I: BV711. J: BV605. K: BV421. L: BUV496. M: PE. N: Alexa Fluor 





8.4 Appendix 4: 16 Colour Run 
 
Figure S7. Percentage of stimulated ILT cells expressing PLZF and CD26 
PBMC were stimulated for 6 h in PMA/ionomycin (50 ng/mL and 1 µg/mL, respectively), stained using a 
16 colour panel and measured using spectral flow cytometry. Analysis was performed on one replicate of 
N = 10 participants. Graph illustrates the percentage of the various ILT cell subsets that were either 
double positive for PLZF and CD26, or double negative. Data was analysed using FlowJo™v10 and 
GraphPad Prism (v8). 
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